<SEC-DOCUMENT>0000950170-25-065618.txt : 20250507
<SEC-HEADER>0000950170-25-065618.hdr.sgml : 20250507
<ACCEPTANCE-DATETIME>20250507160510
ACCESSION NUMBER:		0000950170-25-065618
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250507
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250507
DATE AS OF CHANGE:		20250507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Revolution Medicines, Inc.
		CENTRAL INDEX KEY:			0001628171
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				472029180
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39219
		FILM NUMBER:		25921205

	BUSINESS ADDRESS:	
		STREET 1:		700 SAGINAW DR
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		415-766-3638

	MAIL ADDRESS:	
		STREET 1:		700 SAGINAW DR
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rvmd-20250507.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-07T13:15:42.6722+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:rvmd="http://www.revolutionmedicines.com/20250507" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_788a7e4e-8088-4a9d-b94e-871f682d4152" name="dei:EntityCentralIndexKey" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe">0001628171</ix:nonNumeric><ix:nonNumeric id="F_568e1637-d34c-459f-ba60-7f77e0b2ebba" name="dei:AmendmentFlag" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="rvmd-20250507.xsd"/></ix:references><ix:resources><xbrli:context id="C_1078c484-edf1-40c0-b029-9033e5efacfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628171</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-07</xbrli:startDate><xbrli:endDate>2025-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c9cfa7a-b8da-4cf8-99ca-91f02e0e9887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628171</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rvmd:WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-07</xbrli:startDate><xbrli:endDate>2025-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b5f0c1d-63de-4699-b182-dc1b9bf951ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628171</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rvmd:CommonStock00001ParValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-07</xbrli:startDate><xbrli:endDate>2025-05-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4410ee01-7184-43bd-94a0-ede9fb8062f6" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_d9022b5e-e0f1-4feb-acf7-08df08e0a6ec" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">May 07, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01bcf545-306c-426f-94ae-90740e06e8d6" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revolution Medicines, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_546d3bfc-f626-46fa-a862-ce5869c769cb" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_43ce771a-f29e-48dc-9809-36df2915e7bc" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-39219</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6c3954be-9cfe-4abd-8046-cad8c357a6c7" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">47-2029180</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ad9fca0f-72a5-4377-bbc0-6e103bccd2f3" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">700 Saginaw Drive</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b7e12a65-a97f-46d5-a910-13ad6028de46" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Redwood City</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_65d55536-12d1-49df-b223-c607a971c8e6" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_50196c82-16c7-41c7-afd4-86e72cad63fb" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94063</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_120c8136-5962-4a86-a605-c271afd26f3b" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_994e511f-e53e-442b-9061-1d96781ef4ce" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">481-6801</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bf4912b-0d88-40c7-aa67-2c267b43756d" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f700e850-d1e0-4379-bd6e-a624cd70369e" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f9b6bfc-4bfc-486c-8345-47a9966280b4" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c047a7b-9a65-4acb-bbd4-9ad47bea6108" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b327b2c7-f051-4268-8665-ca375934f270" contextRef="C_6b5f0c1d-63de-4699-b182-dc1b9bf951ec" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_71497839-a898-415f-b6fc-aa429f890312" contextRef="C_6b5f0c1d-63de-4699-b182-dc1b9bf951ec" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RVMD</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5d61bf29-30c2-477c-ba5f-c8ea4a0544a5" contextRef="C_6b5f0c1d-63de-4699-b182-dc1b9bf951ec" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_418e1fc5-73be-4c04-8323-e9dd30e3018b" contextRef="C_5c9cfa7a-b8da-4cf8-99ca-91f02e0e9887" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase 0.1112 shares of common stock expiring 2026</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1a172c00-1e6b-44da-8256-270014990e7e" contextRef="C_5c9cfa7a-b8da-4cf8-99ca-91f02e0e9887" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RVMDW</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9d1a2e28-06c5-4587-86b0-792355c12c12" contextRef="C_5c9cfa7a-b8da-4cf8-99ca-91f02e0e9887" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_ba2085c1-0333-4d3b-b9c5-a98e600a1d3e" contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 7, 2025, Revolution Medicines, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in this Current Report on Form 8-K and the attached Exhibit 99.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:11.76%;box-sizing:content-box;"/>
     <td style="width:88.24%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="rvmd-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release, dated May 7, 2025</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">        </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">REVOLUTION MEDICINES, INC.</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 7, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mark A. Goldsmith</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark A. Goldsmith, M.D., Ph.D.<br/>President and Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rvmd-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img162218922_0.jpg" alt="img162218922_0.jpg" style="width:218px;height:70px;"></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:16pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:16pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this year</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#242424;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#242424;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">New non-small cell lung cancer clinical data from </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">RAS(ON) inhibitor portfolio </font><font style="color:#242424;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">support strategies for first-line metastatic and earlier lines of treatment</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#242424;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#242424;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Anthony Mancini joins as chief global commercialization officer</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">REDWOOD CITY, Calif., May 7, 2025 (GLOBE NEWSWIRE)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2025, and provided an update on corporate progress.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The company continues to make meaningful progress on its 2025 strategic priorities:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Execute pivotal trials with daraxonrasib monotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In RASolute 302, a global Phase 3 trial in patients with previously treated PDAC, the company continues its strong pace of enrollment in the U.S. and has begun enrolling patients in the EU and Japan. The company expects to substantially complete enrollment this year to enable an expected data readout in 2026.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">For RASolve 301, </font><font style="color:#242424;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">a global Phase 3 trial in patients with previously treated NSCLC, the company is currently activating study sites.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Advance daraxonrasib into first-line metastatic and earlier-line randomized pivotal trials in patients with PDAC</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Planning continues for registrational trials for daraxonrasib as first-line (1L) treatment for patients with metastatic PDAC and as adjuvant treatment for patients with resectable disease, and the company expects to initiate both studies in the second half of this year.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Generate sufficient data to inform development priorities for the mutant-selective inhibitors elironrasib and zoldonrasib and prepare to initiate one or more pivotal trials either as monotherapy or in a drug combination</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The company expects to initiate one or more pivotal combination trials in 2026 that incorporate either zoldonrasib or elironrasib. The company believes the updated data shared today support this approach.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Last month, zoldonrasib monotherapy data in patients with previously treated KRAS G12D mutant NSCLC were featured in a late-breaking oral presentation and included in the press program at the American Association for Cancer Research (AACR) Annual Meeting.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The company today announced updated elironrasib monotherapy data in patients with previously treated KRAS G12D mutant NSCLC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The company today also announced several clinical combination updates in NSCLC, including daraxonrasib with pembrolizumab, elironrasib with pembrolizumab, and first data for the RAS(ON) inhibitor doublet combination of daraxonrasib with elironrasib in NSCLC.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Progress earlier-stage pipeline, including advancing next-generation innovations from the company&#x2019;s highly productive discovery organization</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Last month at AACR, RMC-5127, a RAS(ON) G12V-selective inhibitor, was highlighted in a New Drugs on the Horizon presentation. This program is on track to reach a clinic-ready stage later this year to enable expected Phase 1 initiation in 2026.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Grow commercial and operational capabilities and increase pre-commercial activities in support of a potential launch</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The company continues building its commercialization capabilities in the U.S. and welcomed Anthony Mancini as chief global commercialization officer and member of its senior management team. Mr. Mancini, who brings substantial experience from a</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:3.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">decades-long career in the biotech and biopharmaceutical industry, will oversee commercialization strategy and operations and will contribute additional strength both to the company&#x2019;s commercialization approach in the U.S. and its evaluation of options for reaching patients outside of the U.S.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;We are executing well in our ongoing registrational studies of daraxonrasib in patients with previously treated PDAC and NSCLC, and continuing preparations to start the earlier-line PDAC trials this year. Today we&#x2019;ve shared important data from all three of our clinical-stage investigational RAS(ON) inhibitors that reinforce exciting opportunities in NSCLC,&#x201d; said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;As we continue growing our commercial and operational capabilities and advancing launch readiness activities, I&#x2019;m pleased to welcome Anthony Mancini to our executive team.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Clinical Data Highlights</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Data presented today, including items first shared at last month&#x2019;s AACR meeting, create exciting opportunities for the company in both previously treated and 1L metastatic NSCLC, including development approaches with mutant-selective inhibitors and drug combinations.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Zoldonrasib monotherapy in previously treated G12D NSCLC patients</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Zoldonrasib, the company&#x2019;s RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant NSCLC. The company believes these results support further evaluation of zoldonrasib as monotherapy and in combinations.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">On April 27, 2025, the company </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">presented</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> initial clinical results from the zoldonrasib monotherapy trial. In 90 solid tumor patients treated at the candidate recommended Phase 2 dose of 1200 mg once daily (QD), as of a December 2, 2024 data cutoff, zoldonrasib was well tolerated with predominantly low-grade treatment-related adverse events (TRAEs). Grade 3 TRAEs were reported in 2% of patients and there were no Grade 4 or 5 TRAEs.</font><font style="color:#3f3f3f;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The mean dose intensity (MDI) was favorable at 98%.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Preliminary antitumor activity was assessed in 18 efficacy-evaluable patients with previously treated NSCLC. The objective response rate (ORR) (confirmed or pending confirmation) was 61% and the disease control rate (DCR) was 89%.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:3.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Elironrasib monotherapy in previously treated G12C NSCLC patients</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Elironrasib, the company&#x2019;s RAS(ON) G12C-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with KRAS G12C NCSLC who were previously treated with immunotherapy and chemotherapy.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Today, the company shared data for 36 patients who were treated with elironrasib monotherapy at the candidate monotherapy recommended dose of 200 mg twice daily (BID) as of an April 7, 2025 data cutoff. Elironrasib was generally well tolerated with predominantly low-grade TRAEs. Grade 3 TRAEs were reported in 19% of patients and there were no Grade 4 or 5 TRAEs</font><font style="color:#3f3f3f;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. The </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">MDI was favorable at 94%.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">At the 200 mg BID dose, the ORR in NSCLC patients was 56%, and the DCR was 94%. The estimated median progression-free survival (PFS) in these patients was 9.9 months.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Combinations in NSCLC</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The company presented several datasets that support combination strategies to enable its goal of improving treatment outcomes for patients with RAS mutant NSCLC in the 1L metastatic setting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Daraxonrasib and pembrolizumab with or without chemotherapy</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Daraxonrasib, a RAS(ON) multi-selective inhibitor, demonstrated acceptable tolerability and encouraging preliminary antitumor activity in combination with pembrolizumab with or without chemotherapy.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Today, the company shared data for ten patients in the 1L NSCLC setting treated with daraxonrasib and pembrolizumab, as of a February 10, 2025 data cutoff. No new safety signals were seen, and the overall safety profile was consistent with those of daraxonrasib alone and the standard of care agents.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Hepatotoxicity did not appear as a safety signal (no Grade 3 or higher events) in the combination of daraxonrasib and pembrolizumab with or without chemotherapy. No Grade 3 or higher AST or ALT elevations were reported and there was also no evidence of increased immune-related adverse events, such as colitis or pneumonitis, with the addition of daraxonrasib to pembrolizumab.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:3.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Daraxonrasib achieved a favorable MDI of 93% in combination with pembrolizumab and 90% with the addition of chemotherapy.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Of the seven 1L patients who had sufficient follow up to have had a tumor assessment, preliminary antitumor activity was encouraging.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Patients selected for treatment with daraxonrasib and pembrolizumab had tumors with a tumor proportion score (TPS) greater than or equal to 50%, consistent with a population where pembrolizumab is the preferred standard of care. Among seven efficacy-evaluable patients treated with the combination, the ORR was 86% and the DCR was 100%.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Patients selected for treatment with daraxonrasib with pembrolizumab and chemotherapy had tumors with TPS scores of less than 50%, where pembrolizumab and chemotherapy is the preferred standard of care. Among ten efficacy-evaluable patients treated with the combination, the ORR was 60% and the DCR was 90%. The company believes these data collectively support continued development of daraxonrasib with standard of care in RAS mutant NSCLC in the 1L metastatic setting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Elironrasib with pembrolizumab in 1L RAS G12C mutant NSCLC</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Today, the company shared data for eight patients with 1L KRAS G12C NSCLC from the combination of elironrasib with pembrolizumab, which showed acceptable tolerability and encouraging preliminary antitumor activity. As of a February 10, 2025 data cutoff, Grade 3 or higher TRAEs were reported in 25% of patients, and no new safety signals were observed. The MDI was favorable at 85%.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Among five efficacy-evaluable patients with 1L NSCLC with a TPS score of greater than or equal to 50% (where pembrolizumab monotherapy is the preferred standard of care), the ORR and DCR were both 100%.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">RAS(ON) inhibitor doublet of elironrasib with daraxonrasib in NSCLC</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Today, the company presented data that demonstrate acceptable tolerability and encouraging antitumor activity of the RAS(ON) inhibitor doublet of elironrasib with daraxonrasib in NSCLC patients previously treated with a KRAS G12C(OFF) inhibitor.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:3.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of a February 10, 2025 data cutoff, in 33 patients treated with elironrasib at 200 mg BID and daraxonrasib at doses ranging from 100 mg to 200 mg daily, Grade 3 TRAEs were reported in 46% of patients. There were no Grade 4 or 5 TRAEs. Hepatotoxicity was not observed as a safety signal (no Grade 3 or higher events) and QT prolongation was limited with one asymptomatic Grade 3 event (3%).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The MDIs were favorable at 95% for elironrasib and 85% for daraxonrasib.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The combination of elironrasib with daraxonrasib showed encouraging preliminary antitumor activity in patients with NSCLC who have been previously treated with a KRAS G12C(OFF) inhibitor. The ORR was 62% and the DCR was 92%.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The company believes the preliminary results described for the above pairwise combinations support its goal of developing a chemotherapy-sparing triplet combination including elironrasib, daraxonrasib and pembrolizumab in patients with first-line metastatic RAS G12C NSCLC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial Highlights</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">First Quarter Results</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash Position</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">: Cash, cash equivalents and marketable securities were $2.1 billion as of March 31, 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">R&amp;D Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">: Research and development expenses were $205.7 million for the quarter ended March 31, 2025, compared to $118.0 million for the quarter ended March 31, 2024. The increase in expenses was primarily due to increases in clinical trial expenses and manufacturing expenses for daraxonrasib, zoldonrasib and elironrasib, and personnel-related expenses and stock-based compensation expense related to additional headcount.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">G&amp;A Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">: General and administrative expenses were $35.0 million for the quarter ended March 31, 2025, compared to $22.8 million for the quarter ended March 31, 2024. The increase was primarily due to increases in personnel-related expenses and stock-based compensation expense associated with additional headcount, and an increase in commercial preparation activities.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net Loss</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">: Net loss was $213.4 million for the quarter ended March 31, 2025, compared to net loss of $116.0 million for the quarter ended March 31, 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:3.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Financial Guidance</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revolution Medicines is reiterating projected full year 2025 GAAP net loss guidance of between $840 million and $900 million, which includes estimated non-cash stock-based compensation expense of between $115 million and $130 million. Based on the company&#x2019;s current operating plan, the company projects current cash, cash equivalents and marketable securities can fund planned operations into the second half of 2027.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Webcast</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revolution Medicines will host a webcast this afternoon, May 7, 2025, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). To listen to the live webcast, or access the archived webcast, please visit: </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">https://ir.revmed.com/events-and-presentations</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Following the live webcast, a replay will be available on the company&#x2019;s website for at least 14 days.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">About Revolution Medicines, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company&#x2019;s R&amp;D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company&#x2019;s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company&#x2019;s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">www.revmed.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and follow us on </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered &#x201c;forward-looking statements,&#x201d; including without limitation statements regarding the company&#x2019;s financial projections; the company&#x2019;s development plans and timelines and its ability to advance its portfolio and R&amp;D pipeline; progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company&#x2019;s candidates being studied; the company&#x2019;s expectations regarding timing of clinical trial initiation, enrollment and data readouts or disclosures; the company&#x2019;s plans to initiate registrational trials for daraxonrasib as first-line treatment for patients with metastatic PDAC and as adjuvant treatment for patients with resectable disease; the company&#x2019;s plans to initiate one or more pivotal trials that incorporate either zoldonrasib or elironrasib; the company&#x2019;s expectation that RMC-5127 will be its next RAS(ON) inhibitor to enter clinical development and that a Phase 1 study for this compound will be initiated; potential additional development opportunities in the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:3.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">company&#x2019;s pipeline, including RMC-0708 (Q61H) and RMC-8839 (G13C); and commercial strategy and priorities, including its commercialization approach in the U.S. and its evaluation of options for reaching patients outside of the U.S.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Forward-looking statements are typically, but not always, identified by the use of words such as &#34;may,&#34; &#34;will,&#34; &#34;would,&#34; &#34;believe,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;anticipate,&#34; &#34;estimate,&#34; &#34;expect,&#34; and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company&#x2019;s development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company&#x2019;s programs&#x2019; development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company&#x2019;s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company&#x2019;s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company&#x2019;s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines&#x2019; Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on May 7, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Revolution Medicines Media &amp; Investor Contact:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">media@revmed.com</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">investors@revmed.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:3.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">REVOLUTION MEDICINES, INC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">CONDENSED CONSOLIDATED STATEM</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ENTS OF OPERATIONS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share data)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(unaudited)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:49.244%;box-sizing:content-box;"></td>
     <td style="width:3.445%;box-sizing:content-box;"></td>
     <td style="width:5.318%;box-sizing:content-box;"></td>
     <td style="width:13.986%;box-sizing:content-box;"></td>
     <td style="width:2.221%;box-sizing:content-box;"></td>
     <td style="width:3.878%;box-sizing:content-box;"></td>
     <td style="width:1.285%;box-sizing:content-box;"></td>
     <td style="width:1.285%;box-sizing:content-box;"></td>
     <td style="width:1.525%;box-sizing:content-box;"></td>
     <td style="width:1.657%;box-sizing:content-box;"></td>
     <td style="width:9.22%;box-sizing:content-box;"></td>
     <td style="width:1.477%;box-sizing:content-box;"></td>
     <td style="width:3.878%;box-sizing:content-box;"></td>
     <td style="width:1.585%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:28.8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Three Months Ended M</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">arch</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;31,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:13.7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="4" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:13.7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.85pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:13.7pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">205,749</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">118,021</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.95pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:13.7pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">35,011</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">22,838</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.1pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:13.7pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">240,760</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">140,859</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:13.7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(240,760</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(140,859</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:11.5pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other income (expense), net:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:13.7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:13.7pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Interest income</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">24,915</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">23,760</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:7.2pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:13.7pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Other expense, net</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(10</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(2,809)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:28.1pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:13.7pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liability and contingent earn-out shares</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,439</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">3,905</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.1pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:13.7pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total other income, net</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">27,344</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">24,856</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net loss</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(213,416</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(116,003</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:25.9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders - basic and diluted</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(1.13)</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(0.70)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:38.9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-average common shares used to compute net loss per share, basic and diluted</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">188,145,904</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">164,729,200</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:3.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">REVOLUTION MEDICINES, INC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">SELECTED CONDENSED CONSOLIDATED B</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">ALANCE SHEETS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">(in thousands, unaudited)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:48.205%;box-sizing:content-box;"></td>
     <td style="width:9.818%;box-sizing:content-box;"></td>
     <td style="width:1.699%;box-sizing:content-box;"></td>
     <td style="width:11.592%;box-sizing:content-box;"></td>
     <td style="width:1.09%;box-sizing:content-box;"></td>
     <td style="width:1.1%;box-sizing:content-box;"></td>
     <td style="width:0.118%;box-sizing:content-box;"></td>
     <td style="width:9.252%;box-sizing:content-box;"></td>
     <td style="width:16.902%;box-sizing:content-box;"></td>
     <td style="width:0.224%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:15.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" rowspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">March 31,</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="3" rowspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2024</font></p></td>
    </tr>
    <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.1pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.25pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.25pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.25pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="border-top:0.25pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.25pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.25pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:15.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,102,675</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,289,299</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.1pt;background-color:#d1effb;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Working capital (1)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">1,975,983</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,163,718</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,365,353</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,558,301</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.1pt;background-color:#cff2ff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total liabilities</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">287,203</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">293,097</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Total stockholders' equity</font><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,078,150</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2,265,204</font></p></td>
     <td style="background-color:#deeaf6;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Aptos;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Working capital is defined as current assets less current liabilities.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri Light',sans-serif;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:3.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img162218922_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img162218922_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *!""$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MO!?VBOVG/@9^RC\/KOXF_'KX@Z-X"\+PN]M8?;FFN];\1:FJ>8FC>%O#UA'<
MZUXBU:12':STJRN6M;???7[6FGP7%W#48RG)1A%RE)VC&*;;;Z)+5LSK5J6'
MI3K5ZM.C1IQ<ZE6K.-.G"*WE.<FHQ2[MI'O5%?QI?M;?\'(/QC\5WVH^&_V/
MOA_I7PG\+I)/!:?$CXCV.F^,OB/J42L/L^HZ?X4=KOP'X28@LLVFZJGQ$\X+
M%,E_9LTEJ/P7^+_[8W[5WQYN;N?XO_M$?%_QW#>-(TFD:QX[U\>&8A)(LKQ6
M/A.RO;3PQIMNTB(_V?3M)M8 R1D1CRUQZU')L342=64**?1^_/YJ+45Z<]^Z
M1^>YEXEY-A)RI8&AB,SG%M.I"V&PS:Z1JU8RJRUNN98?D>\9233/]/"^\9^#
M],NIK'4O%?AK3[VW*K/9WVNZ7:74#,BR*LUO/=1S1%HW1U#HI*,K#*L"=^WN
M+>[MX+NTGANK6ZABN+:YMY4FM[BWF19(9X)HV:.6&:-EDBEC9DD1E=&*D$_Y
M)<J8)/\ D_\ UQW]O2NN\$_$_P")WPNU&/6?AE\1O'?PZU>*0S0ZKX$\7^(/
M"&I13$Q$R1WWA_4=.N8Y"8(")%E#YABY_=H1T/(M-,3KYT;)_-5';[F>+#Q6
M7.O:9':#>KAF/--*^Z4L%%2=NG-&[ZH_UC**_P ]G]FG_@OK_P % /@#>V%E
MXV\;:;^TAX&MWC2Z\-_%^RCN?$GV4$^>^F?$G1HK'Q@FHRJ%6.Z\3W7B^PMB
MN]=(D+R[_P"L3]@/_@L3^RI^WF+#PCH^I3?"+XZRVWF77P8\?:C9B_U6=$ED
MN?\ A7OB=([+2_']M!##).]O:6NE>)X;6.6]O?"]E91_:6\[$Y;B<,G)Q52F
MMYT[R27]Z+2E'S=G'^\?99+QMD6=5(X>G7E@\9.RCA<:HTIU)/I1JQE*C5;?
MPP5159;^R5G;]8J***X#ZX**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HK@_B;\4/AY\&?!.N_$?XI^,-"\"^!_
M#5HUYK/B/Q#>I96%K&.(H(\[I[W4+R7;;:=I=A#=:GJ=Y)#9:=:75W-%"_\
M(;_P42_X+I?$/XT#7OA)^R+/K7PK^%,PN]+UGXHMYNF?$_Q[:;O+=M >,I<_
M#GPY=J'*FUD_X3/4+4P-=:AX=CFU'0).G#82MB96IQM%/WJDM(1VTOUEK\*N
M^NBU/"SOB'+<AH^TQ=7FKSBW0PE)J6(K/9-1NE3IW^*K4<8*S4>:=H/]B/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>TE%3,.:+KP/\\X_J/3VK*FBZD#U.?Z__%?G[UT3IG((Y'Z_YZBLR:/KT_\
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MO3FMN5 P)X_^O_@>]9[IC((X/Z?Y[>H]:!&(Z9R#^'O_ /6/^>E9TT?7_/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH ***^)_VN/V[O@Q^R1HTT'B._'BSXEW=F+CP_\
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M_,WHKT_[!P?_ #\Q/_@=+_Y2?#?\1:XC_P"@+)/_  FQ_P#\\C_3(_XB"_\
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MM)VWU,<34E1P]>M%)RI4:M2*E=Q<H0E)*233:;2O9IVV:W/@#_B(+_X)#?\
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MKU&G*[22T11117$?3!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]\]_\1_.J$T>>0/\_P"([>H]:#&4;/R>QSLB;2?0]?\ 'Z'_ .M5":/K]/\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "OY:/^#KG_ ),W_9S_ .SF8?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3E72E)?LW1117DGZ"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?_K_ ,>_OSS67-%UX_S_ (CMZCUK6$NC^7^7]=/0RG'JOG_G_77U,&5,C/\
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MF1:?:[A)<R@F6]U"Y"A6N]0O),S7=P1]UG;RX8\6]M'!;I'"G?1OG!'X^_\
M^O\ G]*X:N(E.ZC[L?\ R9^KZ>B^;9]%@\LI47&I5M4KK6.EX0ETY4U[SO\
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M'TZ5ERI@D_Y/_P!<=_;TJS*4;KS6W^1B2)@G(&#V_P _F/3VJA-'U_//]?\
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MNER6D6IM:7(TZ74(9KBPCOS"XLY+V"VGMKB>T2X\MKF&"YMYI(0Z13Q.RR*
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M9P4I4Z$\7F4XMJ^#H*-'F6]ZN)G04H_WJ4:L7T;6I_IMT5_D1^+OVN/VK?B
M\TGCW]IS]H3QN]Q%<P3OXN^-'Q(\2O/#>0Q6UY#,VL^);TR175O!#!<QN62>
M&&**4.D:*/+O^%C_ !#_ .A\\9_^%1KG_P G5UKA^5M<5%/LJ+:^]U%^1\[/
MQ@PZDU3R&M*/1SS"$)?.,<)42Z_:?XZ?[%M%?Y 7AG]HG]H'P6R-X.^.GQC\
M)M&\TL;>&?B=XUT%DDN(Q#<2(=+UNU*O/"!%,ZD-+& CEE %?;7PJ_X+/?\
M!4'X/S02>&_VROBWXAAAE#R6GQ5OM*^,\-U'O#2V\\OQ8TOQC?+%,NZ(R6MY
M;7<",6M+FVF6.5)GD%9+]WB*4G_?C*"^^/M/R.C#^+V6SDEB\HQM".EWAZ]#
M$M=_=J+"7MZJ_P"!_J1T5_#%^SQ_P=8_'_PW/I^E_M._L]?#GXI:,CQV]WXH
M^%6I:Q\,O%\=L2GF:A=Z1K<_C7PMKVH(?-*V6GIX(L9U,,?G6K12SW']*?[&
MW_!9+]@C]MVXTOP[\-/BY%X)^)VJ-%%;?!_XQ6UKX!\?75W,H,=CH7GZA?\
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M'_1NG[,W_?GXI_\ SP:]#^Q<?_)3_P#!L?\ /^K/RO\ )?\ $3>$O^@K%?\
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M7OBK_LLWP@_].^H5_G.U_HQ?\'+?_*+WQ5_V6;X0?^G?4*_SG:^OR+_<I?\
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MO\J'BKQ9XJ\=^(M8\8>-_$WB#QEXM\0WLFI:_P"*/%6LZCXA\1:YJ,P EO\
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MYZ7Y3_S9^&>,#?UG(E=V5#'M+HFZF%N[=W97[V78****^A/QH*_MC_X-*O\
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MTK-FBZ\?Y]?\?S]ZW94[C'^>W]1Z=.*HR)D9 Y_SS_C^?O76?,M=;6[KL_\
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MN6L+*KWFBZF(XX;V ;XFEC*Q7ED9HHK^TLYW$5>2.G53^'^?YC_]=?U0^-?
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M;4B;2>.#U_'^A_SBJ,T?7K]?Z_AT/Y\4T[._],Q:NK?TC#FCP>.O^>/ZC_\
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MKBVN(HYH9$D16'^D]_P1._X*A6W_  43_9[N=)^(=WIUG^TU\%8M*T+XKZ=
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MOX>U&'5/ UAXIB^&WPZO+.83Z=>^"OAE8V_@[3]9TR822B73_%=_I>I^,8)
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MOP*^.GB(1_#34M6N,VOPR^-&KM!;:?90W,TH^P^%/B=-'!H=]9(LMK9>-I=
MUB&/3H-6\6ZC=?WW5_C2VUS<6=Q;WEG<36MW:S17-K=6TLD%Q;7$$BRP7%O/
M$R2PS0RJLD4L;+)'(JNC!@"/]0W_ ((Y_MQ+^WA^P]\-_B-K^IK??%SP O\
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M@_<VRZEX6T#3-8NX+;,)U/4KZX,EQ-/+=3_Z'_\ P6,_:;/[*/\ P3J_:/\
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M30-5A9K77O"GB&W@EF2Q\1>&=7AN]'UBT$CHEW:O+;2W%G-;7$W^0[7]*_\
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MUE^T;XQ\::\\2S7_ (.^!FG:;X-\+6%UM0-8GQGXSTKQ+K_B6Q#B5C>0>%?
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M9^ZE%%%?+G[L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ$9]Q_GTZB@T-N-]I'IVY]>WX]O?UK5ADZ<C_/&3]>A]#Z5@1.",<?\ U_\
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M^5;DL>>?K].?7V/Z?I6>Z8R#^'M_]<?YZT".?FBZ\?Y_P/;T/I6<Z=0?P/\
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M6+MJ?0\+Y%/B+.L+ER<HT6W7QE6.]+"46G6DG9I3G>-&DVFE5JPYE:Y^^_\
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M9'Q7HM@V7@\.^(-'):0.)'^\J_B[_P"#4/\ :5E@UC]IC]D/6+YC:ZA8Z/\
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M-;B6*TT34&;,C/X1O9BD.B71;<$T2^==%DWHEC=Z+%;+:W?ZIQ/@XZCM]/\
MZW4?EFKT;[2.X/3GC_)[>_:B-2I1ESTY6O\ $MXOU7GWW71JYSXK!87,*7L<
M334K7Y*BLJM-]Z<[-I]UK&25I1:1_'UXA\/ZSX:U?4= \0Z7?Z)KFD74EEJ>
MDZI:3V.H6%W%C?!=6EPD<T$@!4[70;E977<C*QYR1,@\<CK^'?ZBOZI?V@_V
M6?A=^T=HQA\4V!TGQ;9VS0Z%X[T>*)->TPKN>&WO P6'7-'\UF\_2=0)54EN
M&TVYTN]E6^C_ )\?VA?V6OBE^SIK/V;Q=IAU+PQ=SM'H?CK1X9YO#FK*=S16
M\TS*6T?6/+1VET;4C%<GRYI;&34+&-;V3UL/BJ=?3X*G6#>_G%]5Y;KM;4^
MS7(L5E]YK]_AK^[7BM87VC6BKN#Z<RO!NUFF^5?+$B8)XX/7\>_T-4)H^O\
MA^OU'0^WI6Y+'D$@?Y]/H>WH?2LYTZ@Y]C_GTZ&NH^>,5TSD$<C]?\]169-%
MUX'^>_X]"/Q]ZWI8\?7_ #QZ?3_)JA*@8$\?_7_P/>@&KZ,YV6/!R!_GT]_;
MU'K5&5-PS_G_ /4>_O\ 6MV:+KQ_G_$=O4>O2LR1-I/''Z?_ *C^G2@PDK/R
MZ&(Z8R#^'M_]<?YZUGS1X)X&?\\?0]1Z>U;DT?7_  _SR._MZ50=,Y!'(_7_
M #VK2$NC^7^7]>G8RG'JOG_G_7^9B2)D>GK['UQ_/_)K+FBZ\'TQ_G\P?YUO
M2)@GCZ_XX_G_ )-498\YP/Z_A]1U']>VAF<W-'U_S^/X]\=_6J+KWQR.OO\
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M_P!6'_AZO_P39_Z/B_9F_P##M>$__EA1_P /5_\ @FS_ -'Q?LS?^':\)_\
MRPK_ "GJ*X?[ H?\_P"M]T/\O7^EK]7_ ,1=S;_H59=_X'B?_EA_JP_\/5_^
M";/_ $?%^S-_X=KPG_\ +"C_ (>K_P#!-G_H^+]F;_P[7A/_ .6%?Y3U%']@
M4/\ G_6^Z'^7K_2U/^(NYM_T*LN_\#Q/_P L/]6'_AZO_P $V?\ H^+]F;_P
M[7A/_P"6%'_#U?\ X)L_]'Q?LS?^':\)_P#RPK_*>HH_L"A_S_K?=#_+U_I:
MG_$7<V_Z%67?^!XG_P"6'^K#_P /5_\ @FS_ -'Q?LS?^':\)_\ RPK\K?\
M@M;^W+^P5^T3_P $TOVC_AE\./VK_@-X_P#B+>0_#77?!/A?PI\0_#VN^(]2
MUCPS\6O NMW4.D:59:B;BZFET&SUF"X*)+]GL)KNZ\MC ,?Y^%%72R2C1JTZ
ML:]5NG4A42:A9N$E*STV=K/R?EKR8_Q1S+,,#C,!5RO+XTL;A<1A:DHRQ#E&
M&(I3I2E%.HUS14^:-].9(****]L_+PHHHH _U5O^"3OQ.F^+W_!-O]C'QK=3
M&YO?^%$>#?!^H73ES)=ZE\-+>7X:ZE=SLZJS7%U?>$KBXN' V//)(T9*%2?T
M*K\)_P#@W"\2W.N_\$J?A!I<X<1>"_B!\:?#5GO:-E-M=?$G7?&+F,)%&R)]
ML\678*RM-(9!(XE$31PQ?NQ7Y_BX>SQ6)@E91KU4E_=YY<OX6/[ X>Q#Q60Y
M+B).\JN5X"<V_P#GX\+2]IZ^^I:]=S^.+_@ZR_95^TZ7^SW^V;X?TW,NF37G
MP!^)EW!;[F-C>MJGC/X8W]T\; QPV=ZOC[2KBZGB</-JVAV?GQE;:&7^+RO]
M9'_@H=^S#;?MC_L7?M"_L\FV@N-=\<_#_4I_ CSM#$EI\2O"\D/BSX=7+W,Z
MD6MM_P )EHFC6^IS1M%(^D7&H6WFHD[FO\G:[M+NPN[FPO[:XLKZRN)K2\L[
MN&2VN[2[MI&AN+:YMYE2:"X@F1XIH9422*1&1U5E('T^28CVN%=)N\L/+EWN
M_9SO*#^3YXKLHKT7X5XHY1]1S^&84XVH9M055M*T5BL,H4<1%=-8/#U9/=SJ
MR?FZ]%%%>R?FAN^%_$NM^#/$WAWQAX9U";2?$GA37=(\2^']5MB!<:9K>A:A
M;ZII6H0$@@36=_:V]S$2" \:D@CBO]<C]EKX[:'^T[^SC\$?V@O#OV=--^+O
MPT\)>-WLK9G:/1]6UC2;:;Q!X>8R-(_VCPWKXU/0;L&24+=:;,JS3*!*_P#D
M-5_?'_P:W?M-_P#"Q_V0OB7^S3K6H^?K_P"SC\0VU?PU:37/SQ_#3XNMJ/B"
MRM[.VE)>1-.^(&E^/[F_EMV:"W&OZ5%-%;R3Q27?AY[0Y\-"LEK0G9_X*EHO
M[IJ%O5GZIX49I]5SK%97.5J>9X9SII]<5@^:I%+MS8>>)<GU<(+72W]/M%%%
M?)G]"!7YB_\ !8S]IL_LH_\ !.K]H_XB:=J#:?XQ\3>$9/A'\/9(75+Y?&/Q
M5<^#[?4=-9RL?V[POHNH:YXSBW[E$?AN4B*X8+;R_IU7\4G_  =<?M-C4O&'
M[-_[(.B:@KVWAC2M5^/GQ!LXG:2,ZUX@?4? _P -X9MI$4%]I6CV/Q!O);>0
M27)L?%.FW %O!-&UWVY?0^L8RC3M>*FISTNN2G[S3\I64?62/F.,<T_L?AS,
M\7&7+6E0>%PS3M+ZQBVJ$)0_O4E.5>W:DS^/JBBBONS^3@HHK[$_X)_?LRWO
M[8?[9/[/O[.\$%Q+I?Q ^(.EKXRFMD=I+#X=^'EF\4?$/459'B\N6T\&:-K;
MVA:: 27QM;=95DFCS,YQIPE.3M&$7*3[**;;^Y&V&P]7%XC#X6A%SK8FM2P]
M&"WE5K3C3IQ^<I)'^@#_ ,$%/V4S^RU_P3C^$AUK2_[.\?\ QY>Z^/\ XX$T
M+QWJ#QW:V*>!-.G^T117=O\ V?\ #33/"#76F3*B:?KMYKICC$ES<23?LW53
M3["QTJPLM+TRTM[#3=-M+:PT^QM(D@M;*QLX4M[2TMH(PL<-O;01QPPQ1JJ1
MQHJ* J@5;K\^K595JM2K+XJDY3?E=W2]$K)>2/[$RS 4LKR_!9=1_AX/#4</
M%VLYNG!1E4DE]JI)2J3?64F^I_#!_P '7OQCGUS]HS]F+X#07F_3_AS\'_$?
MQ-O;6%B(UUGXK>+I?#J+>A#MDNK72OA5:SVB3!GL[;5YI(=B:E+YG\GU?M%_
MP<%>.W\<?\%7?VDXDE\W3_!%K\*? FF9QNC31OA-X+O=7B;;)*@\OQ/JNO!-
MI0^7L\V..;S4'XNU]OET%3P6&BE:]*,WZU/WC^=Y:G\M<8XN6-XHSRLW?ES"
MMAHN]_<P36#A;RY:":]0HHHKL/FC0TG2M1UW5=,T/1[.?4=7UG4++2M+T^V7
M?<WVHZC<QV=C9VZ9&^>YN9HH(ER-TCJ,C-?ZZG[+'P*T3]F3]F_X(?L_^'UA
M_L_X2?#+PCX)DNH%*KJNKZ1I%M%XAU^0''^E>(O$!U/7;PJJ(UWJ,[)'&A6-
M?\R?_@DW\,;?XO\ _!23]C'P3>1?:+'_ (7MX/\ &%_;%(WCN]/^&<\WQ*O[
M.=))(U:UN[/PE/;78#%_LTLOE)))LC?_ %5*^9S^J^;#T4]%&=62Z-R?)%_+
MEG][/W'PAP$50SC,Y).<ZM# 4Y6UC&G#ZQ72?:;JX=M?].T%%%%?.G[.%%%%
M !1110 4444 ?Y2O_!4']G2U_93_ &^_VH?@EI.G)I/A?P_\3=1\0>!M.@0I
M:6'@#XA6EE\0O!&FV;;526#1_#/BC3=&9XP56XT^>%L2Q2*OP37]-7_!T]\,
M[7PO^W7\*?B/86Z00_%+]G;P^NK2+Y.^\\2^!_&?C+1+J[?8_G<>&;OPA9*9
MH0N+(B*XF >&T_F5K[_!U76PF'J-WE*E#F?>27+)_.2;/Y#XFP,<MX@S?!02
MC3HXZO[&*5E&A5E[:A%):>[2J06EMMEL%%%%=)X9^L?_  0[^-$OP0_X*A_L
MIZN]V;?2O'_C6Z^"^M6^[;'J,7Q>T;4/ ^@VDWS(2(?&>K>%]2A4-\UUI]N"
ML@S&_P#I^U_CR_![QU/\+_BY\+/B7:R/%<_#OXC>"/'5O+$I:2*?PEXFTS7X
M9(U 8LZ2:>K(H5B6  !Z5_L,*RNJNC*Z.H9'4AE96&596!(96!!!!((.0<5\
MMG]-*MAZG\].<'Y^SDG_ .Y#]Z\(<6YY;F^";NL-C:&)BF]EBZ,J;2[*^#O;
M:[;W;'5_+1_P=<_\F;_LY_\ 9S,/_JK/B#7]2]?RT?\ !US_ ,F;_LY_]G,P
M_P#JK/B#7G9;_O\ AO\ KY_[;(^RXZ_Y)+._^P6/_J11/X-J***^Z/Y3"BBB
M@#_64_X)R?\ */3]@_\ [,S_ &7_ /U2'@>OLROC/_@G)_RCT_8/_P"S,_V7
M_P#U2'@>OLROSNM_%J_]?)_^E,_LK*_^1;EW_8#A/_4>F<9\1_\ DGGCS_L3
M/%'_ *8[ZO\ '2K_ &+?B/\ \D\\>?\ 8F>*/_3'?5_CI5]#P_MB_6A^54_'
MO&'^)P__ (,T_P#2L %%%%?1GXL%?VQ_\&E7_)//VW/^QS^!O_IC^)E?Q.5_
M;'_P:5?\D\_;<_['/X&_^F/XF5YF<?\ (OK^M+_T]3/NO#?_ )+#+/\ KWC_
M /U7XD_K]HHHKXH_IX**** "BBB@#QG]H[_DWKX\?]D9^*'_ *A&N5_D"U_K
M]?M'?\F]?'C_ +(S\4/_ %"-<K_(%KZ?A_\ AXG_ !T__29'X9XP?[SD7_7C
M'_\ IS"A1117T)^-!7]L?_!I5_R3S]MS_L<_@;_Z8_B97\3E?VQ_\&E7_)//
MVW/^QS^!O_IC^)E>9G'_ "+Z_K2_]/4S[KPW_P"2PRS_ *]X_P#]5^)/Z_:*
M**^*/Z>/Y O^#M7_ ))Y^Q'_ -CG\<O_ $Q_#.OXG*_MC_X.U?\ DGG[$?\
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M/T/Y_7_/(K3ADZ?X]?\ ZQZCW]:#5=GNOQ[/^NMS=AD!')Z_YS_0^]7XI,$
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M^59#E&24W3RO T,+S)*=2*<Z]5*VE7$5'.M45U=1E-Q3ORI!1117.>N%%%%
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MB_\ 9]#_ +BV]/;5/^&/Y>\1DEQCF]NJP#:[-Y;@[_?I+7O<****](^("O\
M8-^!FJW&O?!/X.ZY>)#'=ZS\+/A]JMU';+(EO'<:CX2TB\G2W262:5(4EF98
MEDFED6,*'D=@6/\ CY5_K]?LX_\ )O7P'_[(S\+_ /U"-#KYWB#X<+_BJ_E3
M/V;P?;^L9ZNCHY>VO-5,7;\W]Y[-7\M'_!US_P F;_LY_P#9S,/_ *JSX@U_
M4O7\M'_!US_R9O\ LY_]G,P_^JL^(->/EO\ O^&_Z^?^VR/T;CK_ ))+._\
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M_P#!1O\ Y2%_MX?]GF?M0?\ J[_'%<.0?Q\1_P!>H_\ I:/I_%[_ )%V3_\
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M ,I"_P!O#_L\S]J#_P!7?XXKW\@_CXC_ *]1_P#2T?D'B]_R+LG_ .PW$?\
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M_O*D>]1I[?W(^ZMFYV371QON'N.GX=OZCV],5H0R=/Y9_3\>H]_4U@PR=/\
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MG+C<'A\PPF(P.+IJKAL52G1K0?6$U9M/[,XNTH26L)J,HM-)G^-_XL\*>)/
MGBCQ'X)\8Z+J'AOQ;X0UW5O#/B?P_JUN]KJFAZ_H5]/IFKZ3J%L_SP7NGW]M
M<6ES$W*31.N3C-<_7]?O_!S/_P $W/\ A&_$-C_P4+^$>@;-"\5W6C^$/VD=
M+TNVVP:7XJ9(M*\%_%.6&%2D%MXGABL_!WBJYQ! /$5MX7OW2YU3Q3JMV?Y
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M6C_@ZY_Y,W_9S_[.9A_]59\0:RRW_?\ #?\ 7S_VV1V<=?\ ))9W_P!@L?\
MU(HG\&U%%%?='\IA1110!_K*?\$Y/^4>G[!__9F?[+__ *I#P/7V97QG_P $
MY/\ E'I^P?\ ]F9_LO\ _JD/ ]?9E?G=;^+5_P"OD_\ TIG]E97_ ,BW+O\
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M6'CCP9?7L\5K9V7BOP[=W=S.XCAM[:VU>SFGGFD8A4BAB1Y)'8@*BEB<"O\
M8UKYKB#?">E?\Z1^X>#S7LN(%?7VF6.W6SCC[/YV?W,****^</V@**** "N,
M^(__ "3SQY_V)GBC_P!,=]79UQGQ'_Y)YX\_[$SQ1_Z8[ZG'=>J_,BI_#J?X
M)?\ I+/\=*BBBOT<_BH**** /[,/^#1O_G()_P!VH_\ OR=?V85_&?\ \&C?
M_.03_NU'_P!^3K^S"OB<W_Y&.(_[@_\ IBD?U%X=?\D;D_\ W4/_ %:XX_#?
M_@XB^ [_ !L_X)B_%36;"Q%]K_P'\4^"OC?H\:(/.6ST+4)_"?C"99#@I#8^
M!/&?B?5[A,[94TQ1M,BQ%?\ -GK_ &,/B%X%\-_%'P#XX^&?C&R_M+PC\1/!
M_B;P+XJT[*+]O\-^+M%O= URRS)'*@^U:9J%U!EXI$'F9:-QE3_D<?M'? _Q
M5^S5\>OB]\ O&T;KXF^$?Q \3>!M0N&MWMH]5CT/4Y[73M?LXI"S?V9XCTM;
M+7M)DW.L^F:C:3H[)(K'ULAK)TJV';]Z$_:Q7>$THNWE&4;OSFC\\\6\L=+'
MY=F\(OV>*P\L'6DEHJ^&DZE)R?\ -5HU7&/]W#O:VOBU%%%?0'Y %?WI_P#!
MKA^U?:?$7]E?XC?LH:[JF_Q=^SSXSNO%7A"PN;E0\_PI^*-W<ZLT6F6TCF:9
M/#_Q&B\6SZU- !;68\8^'8G2.6[5I_X+*^\?^":_[;'B/]@']KSX:?M":4M]
M?^%;.XE\(?%KPS8,GG>+OA-XGGLXO%NCQ1R201S:EI[6FG>+/#<4UQ;VI\6>
M&M!>]E^Q)<(_%F&&>*PM2E%>^K5*?^.%VE_V\KPOTYKGU'!V=K(,_P 'C:LG
M'"U.;"8VW3"XAQ4IM*[:H5(TL0TDW+V7*E=G^K?17'?#SX@^#/BOX%\(_$SX
M=^(=-\6>!?'GA[2O%7A/Q)I$ZW&G:SH.MV<5]IU];2#!"S6\R&2&14GMY1);
MW$44\4D:]C7PK33::::=FGHTUNFNC1_5T91G&,X2C.$XJ4)Q:E&49).,HR5T
MXR3333LT[H****104444 %-9E16=V5$12SNQ"JJJ"69F) 55 )))  !).*=7
MX"?\' G_  49T[]CS]E75/@AX"U^&']HC]IK0M6\):!:V5S_ ,37P/\ "R]6
M72?'OQ#N5MY$N=,FO[*6[\'>";MY+2>;Q#?ZAK>DO=GP7JUO'M0HSQ%:G1IJ
M\IR2O:ZBOM2?E%7D_)'G9MF>&R;+L7F6+ERT<+2E4:NE*K/X:5&%]'4K5'&E
M!;<TDW979_%I_P %9/VK;?\ ;*_;Z_:!^,NB:DVI^ H_%"_#_P"%TZL3:2_#
MOX=6T?A30=4T]'59HK3Q9-I]_P"-S#./.BNO$]RCK%@0Q_G+117W].G&E3A3
MC\-.$81](I)7\]-?,_D'&XNMC\9BL;B)<U?%XBMB:KUM[2M4E4DE>]HIRM%;
M**26B"BBBK.8^]_^"77P%E_:6_X*!_LH_"1M/;4M'U/XO>&_%'B^T\O?%+X%
M^'4LGQ"\;0W#-^[ABN_#'AC5+%99,KY]U#&B2RR1PR?ZM-?Q*?\ !JE^RG+K
M7Q ^/?[9GB'3&;2O!6CP? KX:W=Q;[[>?Q7XE_LSQ5\1-0LIG0>3J/AWPS:^
M$=)\R)V,EAX]U&!P@/S_ -M=?(9W7]IBU23O&A!1=OYY^_+RT3@GV::>I_1O
MA;EDL%P]/&U(\M3-,5.M!M6;PU!>PHW6]G46(J1>SA4BUH[LK_)K_P""C?\
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MWX]1Z=.*[#Y1JSL8DJ;23S_G_#H?SXJC*G<>_;]/\/Q^M;<B9&?S_P ?\?\
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M@U-R-]I]CT_'M_4>_KFM6&7IS_D_T/?T/I6!$^0!W[8_/_ZX_'FK\,AXR?\
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M>&A)-QJ*$ZM22T56$7*,BBBBO;/RT**** "O[8_^#2K_ ))Y^VY_V.?P-_\
M3'\3*_B<K^V/_@TJ_P"2>?MN?]CG\#?_ $Q_$RO,SC_D7U_6E_Z>IGW7AO\
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M(O?30QI*B17E_P""+?P3>7C /&SW5Q-)?S/;Q//=RL]R9_6/^(H/_@I-_P!
M+]F;_P -?XL_^>97S[R/&IV3HR7=5))?C!/SV/V&GXJ\,3BI2AF=*3WA/"TI
M-.W>GB9Q?:Z?38_T+Z*_SJO$?_!S+_P4[UN$Q:9K/P,\'N8&B%QX<^$D-U,L
MC,&%R%\6Z_XIM_/0#8JF VQ4DO;N^'']-7_!O[^VS^TM^W-^SC\</B/^TY\0
MH?B%XJ\,?'FZ\)^&[NV\'^"/!MOHOAAO GA#78]%M[+P1X<\.V][#;ZCJU]+
M%>ZNFI:NR2K%/J,R1QA<,1E>)PM%UZKI<L7%.,9R<KR:2TY%'=Z^\>KDW'N2
M9[F5/+,!3Q[KU:=6I&I6H4J=%1HP<Y7E]8E4NTK12I--[M+4_>NN,^(__)//
M'G_8F>*/_3'?5V=<9\1_^2>>//\ L3/%'_ICOJ\Z.Z]5^9]E4_AU/\$O_26?
MXZ5%%%?HY_%04444 ?V8?\&C?_.03_NU'_WY.O[,*_C/_P"#1O\ YR"?]VH_
M^_)U_9A7Q.;_ /(QQ'_<'_TQ2/ZB\.O^2-R?_NH?^K7'!7\3W_!TA^PRVB>+
MOA[^WQX%TEO[-\:+I7PC^.IM(2PM_%6CZ<Z?#+QG?% \A76?#.G7/@?4;V8P
MV=FWA7P98Q[[O6 '_MAKQO\ :%^!/P]_:<^"7Q-^ 7Q5TI=7\!?%3PIJ/A77
MK<+$;JT%T$GTS7-*DGCFCM=>\-:Q;Z?XB\/7YB=M.UW2]/OXU,ELE88+$O"8
MFG65W%/EJ17VJ<K<R]5I*/\ >BKZ'K<3Y'3XAR7%Y;+EC6E%5L)5EM2Q=&\J
M,V]U&=Y4:C2;5*K4LKV/\@.BOJK]M3]D3XH?L-_M&_$#]G3XKV;#6?"-\+GP
M]XC@MIX=%\>>"-3:6;PMXY\.R3#$^E:[8H1-$DDTFCZU:ZOX<U!H]7T;4;>'
MY5K[N$XSC&<)*49)2C):IIJZ:]4?R;B,/6PM>MAL13E1KT*DZ5:E-6G3J4Y.
M,X27=236ET]TVM0HHHJC$_HD_P""*'_!:S5?V%-8L_V>/VA[S4_$/[)'B75K
MBYT[5+>UN=6\0? CQ#JTYFO=?T.RM8YK_6? 6KWDC77BWPE:1SWUC=RS>*?"
MEO)JCZWH?BO_ $#/ /Q!\"_%7P=H'Q"^&GB_PYX\\#>*M/AU7PYXM\):Q8Z]
MX?UK3YP?+NM/U33IKBTN$#!HY DI>&9)()ECFCDC7_'/K[G_ &,O^"D'[7_[
M!6NS:C^SM\5]2T7PWJ-V+SQ'\+_$D0\4_"SQ1,?LXEN-4\&ZE(;2RU6>*UMK
M:3Q-X;FT'Q8MG$+*'7H;1Y8'\7,,HCB9.M0E&G6>LXR_AU'W=DW&;ZNS4NJ3
MO)_IW!_B)6R.C3RW-:=7&Y;"T</5IM/%8.'_ #[C&;C&OAX_8IN<)TDVJ<I0
M4*2_U>:*_C]^ /\ P=A>!+K3["P_:C_9:\5Z)J\4<,>I>*?@+XBTGQ)I6H3E
M4$]U:>!?B!?^%[W0[</O9+.7X@^))1&%!NW?.?T"T?\ X.7/^"7VIVWGWOBC
MXT>'9?LEU<_8M8^$.JSW/G6ZN8K#?X?U+7;/[7>E%6U?[7]@1I4^VWMHHD:/
MY^>68ZFVGAJDO.%JB?FG!O\ &S[K1GZ_A>-^%<7!3IYUA*5UK#%2GA)Q?5..
M(C3NULW%RB]U)K4_H HK^;SX@?\ !T3_ ,$[_"]A*_@SPI^T7\3=5>WWV=II
M/@+PUX:TP7),P6#4]4\6^.-*O+.(")#+<:?HFLE1<0>7!,1<BW_%G]K/_@Z$
M_:Q^+5AJGA;]F7X=^$_V8_#]\DMJ?%UU>Q?%'XJ?9GC,+R:=JNL:-I/@SP\]
MTC2N?)\&ZMJNFNT+:9XAAN;87LMTLIQU5I>Q=-=956H)>=M9OY19S9AX@<*X
M"G*7]I1QM1*\:& A+$SGY*HN7#Q_[B5X?,_JJ_X*3?\ !5?]G;_@G!\/[B\\
M:ZG:^./C=KFF/<?#?X$:#J<,?BCQ%+*[06VM>)+A(KM/!?@F"=9'O/$6JVYE
MODM;NS\-Z?KFJ0O9)_FM?M._M+_%O]KSXW>.?C]\;?$3^(O'GCO4VN[GRQ)!
MH^@:3 #!HGA/PQISRS#2O#/AO3EATS1[ 2S3""$W5_=7VJ75]?W7E?C7QOXR
M^)'BK7/'7Q!\5>(?&_C3Q/?2:GXB\6>+-8U#Q!XBUS4)51'O-5UC5+BZO[ZX
M,<<<2R7$\C)#''$A6.-%7EZ^GP&74L%%M/VE:2M.HU;3?E@M>6-]7JVWJWHD
MOPSBSC''<45HQG'ZIEU";EAL%"?->;7+[?$3M'VM9Q;4?=4*,9.-.-Y5*E0H
MHHKT#XX*Z7P9X.\3_$/Q?X6\ ^"=$OO$OC+QMXBT;PGX4\.Z9&)M1UWQ'XAU
M&WTG1=(L8BR*]WJ.HW=M:6ZLZ(995WNJY8<U7]@G_!M+_P $R9]=UY?^"B'Q
MG\.NF@^'9M6T#]F31=6M?W.M^(56ZT3Q9\6_LMQ%Y<^G^' U_P"%/!ER3*C^
M)3XCUB*.UOO#&A7\O-B\3#"4)UIVNE:$>LYOX8KU>K:VBF^A[?#V28CB#-<-
MEN'4DJDE/$UDKK#X6#3KUI:6O&+4::=E.K*G3NG-']1W_!/G]D?0OV'/V0_@
MQ^S?I#VEYJG@OPTM[X\UVT3$?B;XE>)9Y=?\>:XDKHES-8S>(K^]LM 6\,ES
M8^&;'1-*,ABL(@OV=117P4YRJ3E4F[RG)RDWU<G=O[V?UMAL-1P>&H83#P5.
MAAJ-.A1IK:%*E!0A'N[1BE=ZMZO5A7^37_P4;_Y2%_MX?]GF?M0?^KO\<5_K
M*5_DU_\ !1O_ )2%_MX?]GF?M0?^KO\ '%>[D'\?$?\ 7J/_ *6C\G\7O^1=
MD_\ V&XC_P!,1/C.BBBOJ3\&"OZ,?^#7S_E)-KO_ &;-\4?_ %+/AG7\YU?T
M8_\ !KY_RDFUW_LV;XH_^I9\,ZXLQ_W'%?\ 7J7Z'TO!W_)4Y%_V,:'_ *4S
M_0OHHHKX0_K,**** "BBB@ K_)K_ ."C?_*0O]O#_L\S]J#_ -7?XXK_ %E*
M_P FO_@HW_RD+_;P_P"SS/VH/_5W^.*]_(/X^(_Z]1_]+1^0>+W_ "+LG_[#
M<1_Z8B?&=%%%?4GX,%?T8_\ !KY_RDFUW_LV;XH_^I9\,Z_G.K^C'_@U\_Y2
M3:[_ -FS?%'_ -2SX9UQ9C_N.*_Z]2_0^EX._P"2IR+_ +&-#_TIG^A?1117
MPA_684444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^7G[7_
M ,%[_0_$EU\3M!LY+CP[XBEC?Q"EO&\AT;72GERWEPJ*3'I^KA%G-TQ*1ZH]
MS%*T7VFR23]0Z@NK6VO;:>SO+>"[M+J&2WNK6ZBCGMKFWF0QS03P2J\4T,L;
M,DD4BLCHQ5E*DBM*=1TY<RU6S7=?Y]CDQN$AC*+I3?*TU*$TKN$U=)VZIIM2
M75/HTFOYVYH^O^'Z_4=#[>E94T?7C_/I_4?Y-?KEX^_8J\ ^)+J:_P#".K7W
M@>YG9I'L8[8:UH8D)+,;:RGNK.]LP[$@QQZD]K"I5;>TB1!&?S'_ &S[GX!?
ML(^$/^$G^/?QWTR+6M5M[B;P/\,/"/AT:U\3?'KP)./^)3X?N->L(=*TA;J$
M6E[XKUJ[M?#6F2NL$VH2ZE+9:9?>A3JQJRC"',YRV@HMN_R37X[:O0^-QV7U
M\#2JU\2Z-/#TDY2Q$ZU*%**O97=24))R;2C%Q4I2:44Y61Y%K6IZ7X?TV^UO
M7-2L-'T?3+:6]U+5=4NX+#3K"T@4O-=WEY=216]M;Q("TLLTB(@&6;'-?BQ^
MU+_P4L:[DU'P+^SG-)!; 2V>I_%&[M=MQ/DE)HO!>FWD9:WAV91?$6J0)=,[
M2MI>G6QAL]8F^#_VH?VSOB7^TWKUU%?S7/A#X:07IG\/?#;3]3>[L+:.)\VE
MWXCU"*UTP>*M<BP'_M"ZT^TL[:1I&TG2]-6699/E%'Z'\_K_ )Y%>WA\"H6G
M62E+=0WC'M?I)KM\/KHS\KS?B>I7YL/ESE2HZQEB;.-:JMOW:>M*#W3=JK5O
MX>L7TUSJ-]J5[=:CJ5[=ZCJ%_<2W=[?WUS-=WMY=7#M+<7-W=7#R3W-Q<2,T
MDT\TCRR2,SNS.Q-6H9.G/Z_K^/0_K6!$^1@_TZ_X'^=:$,F#S^O\_P >A_/(
MKT3Y:,N;=Z];[OS_ ,_^"='&^0/48Q^';\/U%:$,G3/TQ_,?AU'Y9K"AEZ<]
M/\_F._J/6M%'Z'\_K_GD5$X]5\_\_P"NGH;0ET?R_P OZ_4W(WVD=P>G/'^3
MV]^U:4;Y (/(_4?YX/\ ]>L.)\C!_P G_ ]NG.>M7X9,<$]/_P!63]>A_/BL
MC0W89!QD_P"1_4?J.>:T(GVD#G_/^'4?EQ6&CXP0>#^G^>_J/6M&-\@>O;GI
MCM_4>WI05&5GKL_ZN;\,G3_'_/![>_:M2-\@$'D?J/\ /!_I7.0R=/Y9_3\>
MH]_4UK0R^X_SQG\>A]#Z4&Z=G==#=ADR,9X_S^H[^H]:T(G(..?_ *W^(ZC^
ME8<;X((/!_0_YX/]:T8WR!Z]N>F.W]1[>E!LFFKHW$?H?S]_R]?Y_2M*&7IR
M/\\9_'H?3KQ6##)T_EG]/QZCW]36A&^",'@]/K[_ %_GZ4#.DADZ<_IVZ?IT
M/J/6M)'Z$?B/\^G4?_7KG89.G)_SQD_3H?4>M:T,G^<_YZ=1[>E8R5GY=#:,
MN9>?4W8G!&./_K_X'J/ZU?B?L?\ /O\ X_TK#B?:<=C_ %[?U'O]:T8WR 0>
M>_O_ )[^_I4FL)6=NC_,VH9"#@G_ #Z_T/J/6M6&3IU_/T[?4=1[>E<_&^0"
M#R/\_IT/_P!>NU\$^$O%?Q \2:1X.\$>'M8\5^*=>NTL='T#0;&XU+5-0N6#
M.4M[2U221EAC1YYYF"PVUM'+<W#Q0122*-I)MNR6K;V2[LVC&4I*,4Y2DU&,
M8IN4I-V226K;>B2U;T01.",<?_7_ ,#U']:_2_\ 8P_X)P?%S]J*?3_%VOI=
M_#3X,&5)9O&>J63#5_%-NA#26W@/1[@(VI+,"L+>([T0^'K0M,]M-K%]8S:0
M_P"DG[$G_!(3P_X&71_B5^U-!IGB_P 7IY5]IGPEB:'4O!OAV4$2PMXONT>2
MU\8:G$=OG:-"K^%K:5)(KB;Q-!*CP?N=!!!:P0VUM#%;VUO%'!;V\$:0P000
MH(XH88HPL<444:JD<:*J(BA5 4 5Y.*S%1O3P]F]G5W2_P ">DO\3T[)[GZ'
MD/!M2?)B<W3ITW:4,$FU5GLU]8DG>E%K>E%JKTE*FTXOQKX%_L]_";]G'P;;
M^"/A/X5M- TX".35-3DQ=^(O$M^BE7U3Q)K<J"[U2]<LYC5S'8V$;_8]*LM/
MT^.&TB]JHHKQI2E)N4FY2;NVVVV_-O4_2*5*G1IPI4:<*5*G%1A3IQ4(0BME
M&,4DEZ(****1H%%%% !1110!!=6MM>VUQ97MO!=V=W!+:W=I=11W%M=6UQ&T
M4]O<02J\4T$T3O'+%(C1R1LR.K*Q!_'?]JK_ ()C:=K1U#QY^SA%:Z+J[-)=
MZE\+KJ>.UT/468M)))X/O[AUAT.Z+_=T/4)%T60.5L+W1HK>*RN?V/HK6E6J
M49<T)6[IZQEZK]=&NC1Q8[+L)F-+V6*IJ25W"I'W:M*3^U3G9N/G%WA*UIQD
MM#^,+6-$USPMK.H^'?$ND:EH&O:1<O9:IHVKV5QI^I:?=1X+V]W9W4<4\$@!
M5U61%W(RNI9&4F"-\$<\'I^/;Z'^?-?U4?M&?LG?"G]I/1FB\6:=_9'B^TM?
M(T'Q_HL,,7B'2MC/)!;718+%KFC"5W,ND:B614FN'TVXTR^E%]'_ #R?M"_L
MK?%7]F[6OLGC#3#JGA6\N&BT'QYHT,\WAS502[16]Q*RE]%UAHU9I=&U$QSE
MHYI+"74;*,7K^SA\7"OH_<J?RM[^<7U]-UYK4_.,UR'%9:Y5%>OA+Z5X+6">
MRK0UY'TYDW"6GO*3Y5X'&^0#W'/U_P ]#6C#)T_#_/X?J.W>L*&3!P>V._Z_
MCT/X<UHQO@@@_7V/^?S':MIQZKY_Y_U_F>/"71_+_+^OU.B@EZ<_E^9_Q!^O
M/:M.-\X/?C/;(/\ C_.N=ADZ=?\ ]7^'4?EFM:&3I_C_ )X/;W[5F:IV?Y^:
M[&U&^0#W'/U_ST-:,,G0?Y_R/U';O6)&^"".A]>W^>A_GQ6-XL\;^&? 6BS^
M(/%6KVVD:9!\H>8M)<7,Y4LEI86<2O=7]Y(%8I;6D,LS(KR%!%&[JTFW9)MO
M9+5OY%<\8)N4E&"3ES2:22W=V]%;JVU;YH]$B<@@9^GT_P#K=J^*?CQ^V?X?
M\#K>>&/AFUEXK\7*);:ZUO>)_#/AZ8#:Y62([=>U*)CM^RVLJ:?:3AOMMY+/
M:SZ7+\J?'']J3Q9\25O/#OADW/A3P1)YD$MO#*4USQ! ZM'(NM7<$A6"QFC8
MC^QK)S Z/*E_=ZFC11VWQY+%CIQCIQP/3\#^A_*NNEAOM5/E'_Y+_)?-]#Y_
M'9V_>I8)N.\7B&M7??V46M/\<E?^5*RD3>+_ !3XE\;:[?>)O%FLWVO:YJ#E
M[K4-0F,LI12QCMX4 6&TL[8.R6MC:106=I%B&U@AB58QR$L>02!_GT^A[>A]
M*VY$R">_?C]?J._M6=(F">.._P#GT]/Z<5V;;'RLG*4I.;<I-MR<FW)MZMMN
M[;>[;>NYB.G4'/L?\^G0UGS1X.1[]OT_^)_R:W)H^O7_ #W_  Z$?CQUJA(F
M00>HS_G_  H$8DJ;@3Q_G_'H?SYK,FBZ\?Y_Q';U'K6[(FTGT[\>O?\ 'O[^
MM49H^IQQ_G]1^H_*MHRNO-;_ .9C*-GY/8YV1,$\<'K^/?Z&J$T?7_#]?J._
MMZ"MR:+KQ_A_^H]O0^E9SIU!S['_ #Z=#5&4XWU73?S7_ ,61,Y! R/U'^>1
MZ>U9TB8.0./\\_X_G[UN2QX/'7/^1]#U'^35"5 P)X_^O_@>]!D8DT>1QG_/
M;\.H]>G-9<T?7_#_ #P>_OZ]*WW3&01P?T_SV]1ZUGS1]?Q_7^A_0_E0)JZL
M<\Z8)!Z?Y_4?YZUGS1X[?3_/H>WH>.*W)H^O^3Q_4=_4?E5!TSD$<C]?\]O0
M^E!@U;1F)(F03SGO[8[_ .(_E6=(F,@]#^G]/I6W*A4DX]<_X_7U_/WJC-'G
MIGI_D?4=1_6MHRNM=U_5S&4;/R>W^1_?I_P;)#;_ ,$Y-='_ %<K\3C_ .6I
M\-:_H=K^>7_@V67;_P $Y=<'K^TG\33]?^*5^&P_I7]#5?#9CKCL5_U]E^&A
M_57"'_),9'_V+Z'XQ;"BBBN(^D"BBB@ HHHH **** "BBB@ HHHH **** /P
M!_X.6_\ E%[XJ_[+-\(/_3OJ%?YSM?Z,7_!RW_RB]\5?]EF^$'_IWU"O\YVO
MK\B_W*7_ %_J?^DTS^<?%7_DIZ?_ &*\)_Z>Q04445[)^:A7]?O_  :5?\E#
M_;<_[$SX&_\ I\^)E?R!5_7[_P &E7_)0_VW/^Q,^!O_ *?/B97G9M_R+\3Z
M4_\ T]3/LO#[_DL,E_Z^8O\ ]5^+/[8Z***^(/ZF"BBB@ HHHH **** /\^#
M_@XI_P"";0_98_:$3]J?X6:%]D^ _P"TKX@OKK7+'3[9(=+^'GQPN(;G5O$>
MA11QDBVTCX@6]MJ/CGP_& L4.IIXRTBUM['2]'TB&7^;ZO\ 71_:X_9@^'/[
M9/[._P 3_P!G+XI6V_PO\1_#\NGPZK# L^H^%?$=G+'J/A7QEHRM+!_Q-O"W
MB"UT_6;2%IXH+[[+)IE^9-.OKR"7_*A_:6_9Y^(_[*7QU^)G[/GQ8TS^S/'/
MPP\37GA_4S$LO]GZO9KLNM$\3:)+-'%+<^'_ !3HEQI_B'0KJ2**6?2M2M'G
MA@G,L$?V&3XWZQ0]C4E>M026N\Z6T9>;C\$G_A;;<C^;_$?AC^QLS_M+"4^7
M+LTJ3G:*]S#8UWG6HZ:1A6UKT5HOXU.$5"BK^&4445[!^;A7Z>_\$E?^"A&O
M?\$[/VL?#7Q*NI[Z\^#?CA;3P'\>/#%LUU,E_P"!+Z_BD3Q38:=!YBW7BCX?
MWQ'B+0BMM)>7=HNN>&;:>TM_$]]./S"HJ*M.%:G.E47-"<7&2\GV[-;I[II-
M:HZL#C<3EV,P^.PE1TL3A:L:U&:Z2B]I+[4)*\)P>DX2E&5TV?[(_ASQ%H/C
M#P]H/BWPMJ^G^(/#'BC1=+\1>'->TFZBOM*UO0=;L8-3TC5],O8&>"[T_4M/
MNK>]LKJ%VBN+::.6-F1P3LU_(?\ \&SW_!2IO&'AJ[_X)[?&'7_,\2^"]/U+
MQ1^S=J^J74?G:UX+MV>^\6_"M)IY$FN=0\(/)/XJ\)VJ"\N)?"<_B6Q4V.E>
M#--MY?Z\*^#Q>&GA*\Z,]>5WC+I.#^&2]5HUTDFNA_6G#^=8?B#*L+F>'M'V
ML>6O1O=X?$P25:A+K[DG>#:3G2E3J62F@HHHKF/:/QU_X+#_ /!*SPI_P4C^
M"<5SX9&E>&OVF_A;87]W\'?&UZXLK#6K>9C=:C\,_&MW';7,S^%/$$RF?3+X
M1M<^%/$?D:M:,=-O/$>F:U_FQ?$SX9^/_@UX_P#%GPL^*?A/6O OQ"\"ZU=^
M'_%GA/Q!:-9ZKHVJV; 203QDM'-#-&T5W8W]I+<:?J>GW%KJ.G75U875M<R_
M[$]?CI_P55_X(\?!7_@I%X1?Q/9OI_PO_:>\,Z2MGX'^,%O9.]KK=E9+=267
M@GXG6-HC3Z[X3DGN9/L6JV\;^)/"=PZWFD2WVF_VGX:UKVLKS/ZM:A7;=!OW
M9:MTF]]-W3>[2UB[M)W:?YCQWP*L\4LURJ,(9M""5:BW&$,PA"-H^\[*.+A%
M*%.<VH5(J-.I*/+&<?\ ,JHKZ7_:K_9 _:$_8L^*&H?"3]HKX=ZKX%\36[7$
MVCW\@%]X6\9Z/#-Y,?B/P5XFM0^E^(]$N T3&:SF%YITLHT_6[+2]6ANM/@^
M:*^LC*,XJ<)*49).,HM.+3V::T:]#^>J]"MAJU3#XBE4H5Z,G"K1K0E3J4YK
M>,X22E%KLT@HHHJC(**** "BBB@ HHHH ***_HW_ ."2G_!!#XI?MAWWAKXZ
M?M0Z9XC^$7[+JS6NK:5HEU%/H7Q'^-]FI\^"W\.6MS$M_P"%? 6H*(FN_&]Y
M;PWFM:9.$\#1S_;!XGT7&OB*6&INK6FH16W64GTC%;RD^RVW=DFUZ>4Y/F&=
MXRG@<NP\Z]:;3DUI2HT[VE6KU&N6E2CUE+5NT(*4Y1B_-/\ @B1_P2&\0?M\
M_$ZR^,WQ?TB[TO\ 9$^%_B2 >)IY9)K"Y^,7BK2C!J"_#/PY(D?G'05+VG_"
MP]>M9;66RTB[&AZ)>P:_J/V_0_\ 1FTO2],T/3-.T71=.L=(T?2+&TTO2=)T
MNTM]/TS2],T^WCM+#3M.L+2.&ULK&RM88K:TM+:**WMK>*.&&-(T51S7P\^'
M7@3X2>"/#7PV^&/A'P_X#\ ^#M,AT;POX1\+:9:Z/H6B:;"SR+;6.GV<<<,?
MF32375U,5:>\O)[B]NY9[NXFFD[.OBL=C:F-J\\O=IPNJ5.]U%.UV^\I63D_
M)):)'].\*<+X3AC+_J])JMC*_+4QV+Y;.M52:C"">L</1NXTH/76527OSD%%
M%%<1]0%%%% !36575D=5='4JZ, RLK AE92"&5@2"""""01BG44 ?Y4?_!4O
M]E4_L:_MW?M"?!#3]-;3?!EEXQG\8_#&-8ECM#\,_'T:>+/"%I9-'%##-%X>
ML-4/A.ZDABCB75/#^H0K&GDE1^?=?VJ_\'6/[*W]H^&/V??VR_#^F*UUX=OK
MOX#?$N]@AB,SZ-K)U+Q?\-;V[=-LXM-,U>#QSI<EQ*)81=>(])M@\#R1I<?Q
M55]YE]?ZSA*-1N\N7DGWYX>ZV_.5E+TDC^3.+LI_L7B',L%"')0]L\1A$E:/
MU;$KVU*,>ZI<TJ#?\U*04445V'S04444 ?U$_P#!KA^RM_PLG]JOXE_M2:_I
MBS^'/V=/!?\ PC_A*ZN(8FC_ .%G_%2#4-(CNK-Y=S/+HO@&Q\7PWGV=/,M7
M\2Z3+)-$)HH[C^]>OQZ_X(4_LJ_\,J_\$X_@QI^K:;_9_COXTPW'Q^\>B6W^
MSW@OOB+:V$_A.PND=GGAFT?X<Z?X.TZZM960P:G#J3F"WEFFB'["U\-F=?ZQ
MC*TD[Q@_90_PT]&UY2ES27E(_JK@?*/['X;R^A./+B,3#Z_BDU:7ML6HSC&2
MZ2I4%1HR3OK384445P'UP4444 %%%% '\S?_  7H_P""-\W[7/A[4/VM_P!F
MO083^TIX&\/D>/\ P3IULD=Q\=?!>@6+?9GTZ."(O>_%/PMI]LEGH$<F;CQ;
MH$$'A99)-1TSPQ:2?P$3P36TTUM<PRV]Q;RR03P3QO%-!-$YCEAFBD"O'+&Z
MLDD;JKHZE6 ((K_9;K^;#_@L-_P06\*?MD3^(?VC?V5DT'X=_M/-;M?^*O!U
MT;?1O 'QTFM8L-+>72JEKX.^)=S"BQV_BB1?^$?\2W44%MXO739[RZ\::?[^
M5YJJ*CAL3)^S5E2JO7V:Z0GUY.TM>39^Y;E_(>/. 9YA.KG624D\;).>.P,$
ME];:6N(PZNHK$V7[VEI]9?OP_?\ ,J_^?=17>_$[X7?$;X+>._$?PQ^+/@KQ
M'\/?B!X1U"73/$?A+Q7I=SI&LZ7=QX9?-M;I$,MK<Q-'=:??VS36&I6,UO?Z
M?<W-E<03R<%7U"::33332::=TT]4TUHTULS\'G"=.<J=2,H3A)QG"<7&<)1=
MI1E&23C*+3332::LU<****9(4444 %%%% !1110 458M+2[O[NVL+"VN+V^O
M;B&TL[.TADN;N[N[F18;>VMK>%7FGN)YG2*&&)'DED=4169@#_71_P $BO\
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MR.WMVH-D[JZZF_&^"/3MSUSV_J/?UK2C?."#S_,?YZ^A].*PXGR ,CVQZ_\
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MLSKY+^/7[%OP1^/]Q-K?B#1[KPUXTD0*WC3PE+!INK791-D0UJUFM[G2]<5
ML2>??V3:FD$26UMJ5M#E:]&ACW&T*]Y1V4UK+_MY?:7GOWYCX_->%H56Z^6N
M-&HW>6'D^6C+SI22;IN_V'>G_*Z:5G_,3$Y!QS_];_$=1_2M6&3I_CU_^L>H
M]_6OU.^(7_!,;PW\.M%UCQGXD_:8\.^$? >A6[7VL>(?&?A&'2;71K,2+&OV
MK4&\91V5Q(S/'%;X^QR7EW+%:6]MYLD2O^ /[2WQZ\#1:G?>"/V?/$?BK7_#
MUJTEIJ/Q4UK2HO!]WXF*F2.9O"?A1)]2U3PUI#X62WU/5M;?Q!=QR*QTSP_)
M"PN.^BXXB35%N26\G&2C'R;E%*_9)MM;7LSXS,J%?*(*6/A"C.2?LZ7MJ$ZM
M:SM>%.G4E+D[U)1C!-<KES-1??\ Q8_:)\-?#A)](TP1>)/%X#)_9L$O^@:1
M(1\LFN7<9_=NO+#2[8O?R803_P!GP3QW5?FOXZ\;^*OB#J\FM^*]6FU*[.];
M:(_NK#3;=V#"TTRR0^39VRA44J@::=D$]Y-=7327#YLR;LGDEBS$GDEF)9B3
MR2Q)+9/))).3DUG.G4'\#_GUZ'_ZU>G3I1IK36763W\[=EY?>V?'8K&UL4[2
M?+33O&E%^ZO.3TYI>;VZ)&)(FX'CD=?P_J/\YK-FBZ_C].?Z']#^5;LL>"2!
M_G_ZWZCOQ5&6/() _P __7_0]^:U/.E&SOT?X>7^1SDJ8)/^3_\ 7'?V]*HR
MQY&1CG_./\/3VZUNS1]?\/3^HZ'V]*S9$P2#T.?\_P"%!E.-U=;K\3$=.WY'
M_/Z__JK/ECP<@'C_ #C^H]?>MN:/KT_SW_'H1^//6J,B9!XY[_Y]?3^O%!D8
MDJ9!/^1_]8]_?UK.=,$@]/\ /ZC_ #UK;D3!)[=^/U^A[^]4)H^OTSG_ #W'
MZC\J:=G?^F)I-69AS1=>/\_X'MZ'CBLN:+KU_P ]_P .A_/BNA=,Y!'(_7_/
M;T/I6;-%UX_SZ_X_G[ULFFKHQ:L[/H8$B9!!ZC/^?\*SY$P3Z=_?/?\ H??U
MYK;ECP<@'C_./ZCU]ZHRID9_I_G@]_?UIF,XV=UL_P &8<L><\=?3T_Q''U]
M^E4'3.0>HSCW_P#UUM.F"0>G./;'^'ZU0FCQV_S_ (']#Z=*"#"FCZ_X>G]1
MW]O2LN:/!XQU_P CZ'J/Z5T4B9!]>_MCO_0^WIS69-'U_'C'Z?U7_)H(G&^J
MW7XHP94# G'KG_'Z>OY^]9[I@D$<']/\]JVY$P2>,=_?/?\ Q'\Z]4^ 'P0\
M5?M'?''X5? GP1%O\3?%;QSX?\&:=.R-)!IJ:O?Q0ZAK=Z%^8:=X?TS[9K>I
MR#)BT[3[J0!BF*')03DVDHIMM[))7;?DDKLBG2G7J0HTX2G4JSA3IPBKRG4G
M)1A&*ZRE)I)=6S_08_X(0_"VZ^%G_!,#]G6+4;>2UU;Q_'XX^*-]'(9"'M?&
MGCC7KOPQ<Q+([!([SP7;^&KL+&L<9>=Y C,[RR?K_7&_#KP+X?\ A=\/O OP
MS\)VYL_"WPZ\&^&/ OAJT8J6M?#_ (1T2Q\/Z-;L55%)@T[3[:(E5525R% X
M'95\)7J>VK5:K_Y>5)SMVYI-I?).Q_6^5X-9?EN7X!-/ZG@L-AFUM*5"C"G*
M7_;THN3?5L****R.\**** "BBB@ HHHH **** "BBB@ HHHH _ '_@Y;_P"4
M7OBK_LLWP@_].^H5_G.U_L8>.?A[X ^)^@R>%?B5X'\'_$/PQ+=6U[+X<\<^
M&=%\6Z#+>V;,]G=R:/K]EJ&GO=6KLS6UPUN98&9FB="2:\6_X8K_ &-_^C2_
MV9O_  P_PL_^96O:R_-88*@Z,J,IMU)3YE))6DHJUFG_ "M_<?F/%W &)XES
M6.8TLQH82,<)1PWLJE"I5DW2G5FY\T:D59^T22M=6WU/\CBBO]<?_ABO]C?_
M *-+_9F_\,/\+/\ YE:/^&*_V-_^C2_V9O\ PP_PL_\ F5KN_P!8*7_0-4_\
M&1_^1]?Z>GR__$(,;_T.\+_X25?_ )<?Y'%?U^_\&E7_ "4/]MS_ +$SX&_^
MGSXF5_65_P ,5_L;_P#1I?[,W_AA_A9_\RM>D?#OX'?!7X0S:K<_";X/_"[X
M7W&NQ6D&MS_#OX?^$_!4VL0V#SR6,.JR^&M)TQ]0BLGNKE[2.[:9+=[F=H0A
MFD+<N,SB&*PU6@J$X.HHVDYII<LX2V23?PM?=\O;X<\-L5D>=8'-:F:8?$0P
MDJTI488:I"4_:X:M024I5))6=52=T[I-=3U&BBBO!/UL**** "BBB@ HHHH
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M^C2_V9O_  P_PL_^96OH?]8*7_0-4_\ !D?_ )'U_IZ?CW_$(,;_ -#O"_\
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M,P\),VI2E++<PP>,I7O&&)53"5[=(VC&O1DULY.K33W45>R_SBZ*_MU\8_\
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MD=?A_>>-/A-;JQ>.3$-I\*_%/@RTMTW1*!%;P11A#)$$$<TJ/\QZS_P;<?\
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M#%Y3FV7YE/-L/6A@L33Q$J4<-5A*HH._*I.JU%ONT[=CV2BBBOGS]B"BBB@
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M?757?DGIU['LX++I57&K7C*-'1\E^2I579-QER1?\S5VOAT?,OU3_8K\$?\
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M<W5U<SLD-O;6\*/-//,Z111(TDC*BD@#;<LU\3_M@?MZ? W]CCP^TGC;5?\
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M^OT/?W]:W)HNO'^?\1V]1ZUGNF<@_A[_ /UC_GI70<9B2)N!XZ=?7_\ 6/\
M/I6=(FTGC@]?Q_H?\XK;E3!S_3_/([^WI5&6,$9P.?\ ./ZCT/I0)JZ:[F)-
M'UZ_7^OX=#^?%94T?7\>,?I_5?\ )KH'3J#^!_S^H_\ K5G31=>#T_R/KW!_
MGUH,6K.QS[IU!_ _Y]>A_P#K5GRQD$D#O_D?4?J*W)H^O^'Z_0]#[^M4)$R#
MQR.OX=_J*#&<>JZ[^7_#_GZF)+&",@>OT^GT/Z?I6>Z8R#^'M_\ 7'?_ .O6
MU(FTGC@]?Q_H?\XJC-'UZ_7^OX=#[>E!!AS1X/&.O^1]#U']*H2H&!./7/\
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M>D5.G'D<%HE>*]UQBND5%I;7TB_V;HK/TG5;#7-+T[6=+N%N]-U6RM=1L+E
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MXA?^KO\ V=Z_O\K^ /\ X-5/^4A?QC_[,S^(7_J[_P!G>O[_ "OC<Z_W^?\
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MS,X_Y%]?UI?^GJ9]UX;_ /)899_U[Q__ *K\2?U^T445\4?T\%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5_C0JV#CL?T]_\:_V7J_QGZ^DX>_YC/^Y?_P!SGXGXQ?\ -._]
MU?\ ]Y9?B?:<?3_/X?R[<5JPR].?\CK_ (C^?:L!&[=QT_S_ )X_&K\,G3K_
M /J_PZC\LU](?C,7=>:W_P SI8GR,'_/I^?\^W-:$,F#@]L=_P!?QZ'\.:P(
M9.G^/^>#V]^U:D;Y (ZC^7^>#[T%&W&^""#]?8_Y_,=JTHGR ._;ZCJ/\*PH
M9,@#/'\O_KCOZCUK0B<@XY_^M_B.H_I64XVU6WY/_+^NQK"5U;JOR-R&3I_G
M_(/\^E:T$G3G\_Y_T/\ ,5SR/T/Y^_Y>O\_I6E#+TY'^>_X]#Z>U0;0E;1[/
M\SH(WP00?K['_/YCM6E$^0!W[?4=1_A6'#)GJ>/\C/U!Z^H]:];^#WPE\>?&
M_P <Z9\//AUI(U;Q#J22W)$US%9V.G:;;-$+[5]4O)CMM=.T]9HWGD1)KB0O
M';6=O<WD]O;2IM13;:22NV]$DMVV;PA.I.-.G&4YSDHPA!.4I2;LHQBKMMO1
M)(Y*U\R62.*-'EED=8HXD4N\DCD*B(B@LSR,0J*H)9R H)-?K+^R]_P3C\0>
M*QIWCCX]0ZAX5\,MY-Y8?#Y"]EXJUN//F >(Y<"?POI\JB-9=.0#Q%<1R31R
M-X>GABFG^^?V7/V"OAQ^SS!9>)M>%KX_^*RJDS^*+VU(TKPY.R@O;^#]+G+K
M:F-AL_MZ]5]:G(=[=M)MKF;35^X9$W ^HZ_X_4?_ %J\O$8YN\*#:76ILW_A
M3U7J]>R6Y]WE'#"I\N(S*TYZ2CA$[PCLU[>2TG)/>G%\G\TIIN*XCP_X6\/^
M#]#T[PWX5T;3] T'2+=;73=)TNVCM+*TA4EBL<4:@%Y79YIYG+S7%Q))//))
M-*[M>D3()YSW]L=_\1_*MB1,$Y P>W^?S'I[51D3!R!Q_GG_ !_/WKC4N;5[
M]?7O\SZQP4$HQ244DHI*R26B22LDDM$EHE8PIH^OX\8_3^J_Y-94T?7_ /5U
M[_CT/^37231Y&1_GV_#J.]9<T?7I_P#K_H>AQW]:8C!D3(/'/?\ SZ^G]>*S
MI$VD^AZ_X_0__6K;ECP>!SS^G;ZC]15&6/(X''/Z]OH?T-!C*-MMG^!AS1]?
M\/\ /([^WI5!TSD$<C]?\]16VZ=0?P/^?3H?_KUGS1X)([?YQ^/44$25UY]'
MV,9TZJ?P_P _S'_ZZSIH^O!]/_K?4=1Z^];DJ9&1U_SS^/?\\51D3<#D<C_/
M_P"KU]Z#)KKU^TOU]'^?JCG9HNO^>O\ 0]_?UK-=,9!Z'./;_P#570S1]?\
M/^0?T/Y5E31]?\/\\CO[>G2FG9W_ *9#2:LS$FCQG Y'^?R/;T/I5"1,@GG/
M?VQW_P 1_*MN1,Y! R/U'^>1Z>U9\B8.?\X]?P[_ )ULFFKHQ::=F8,L>#QV
M_P X]?<?Y-494W GC_/]#W_/GMNRQY''3'^1]1U'^369(FTGT[\>O?\ 'O[^
MM,AJUWNGNOU^76WKT,*:+KQ_G_$=O4>M?7_[+G[;OQ:_9COX=,L+E_&'PUFN
M/,U/X?:W>3FR@665I+B\\+7I\Z3PWJ<C/))(;>*;2[Z5V?4M-NIQ!<6_R?-'
MW[<G\OZC]1^59<T>.0/\_P"![>A]*F<(U(N,XJ47NG_6C[-:KH50Q&(P=:%?
M#U94JL-8S@[775-:J47M*$DXR6C31_4/X6_X*;?L@^(- 76-5^(&I>#+Y+=)
MKSPYXC\(>*IM8M79%+0QR>'=(UW2=099"\8_LW4KI_D\R6.*-XV;\[/VM?\
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M)4# G'KG_'Z>OY^]9DT77@_YYQ^'4>H]:WI$P2>,=_?/?_$?SJA-'GD#_/\
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M ,3/O<O_ -QPO_7F'Y!11169V!1110 4444 %%%% !1110 4444 %%%% 'X
M_P#!RW_RB]\5?]EF^$'_ *=]0K_.=K_1B_X.6_\ E%[XJ_[+-\(/_3OJ%?YS
MM?7Y%_N4O^O]3_TFF?SCXJ_\E/3_ .Q7A/\ T]B@HHHKV3\U"BBNX\=?#WQ+
M\.[KPU;^)+-K9/%W@?PC\0O#MTJR?9=5\->,=(@U33KRTDD1/.6VG:\T>^9
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M?_R2M+_L.QG_ *7 ****\D_1#^37]H[_ (->/^&@/VA?CQ\>?^&X_P#A$O\
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M5EJXTWP%^TK-;:9J)V6>F_%:TM1;Z7>N=D<$7C72[.+R=*N)7W!_$6EP1:.
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M<X]L?X?K6W(FTGN#U_'_ !_G5&:/J>._^?J/U'Y4&,HV?D]O\C#FBZ\?Y/\
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M_N4O^O\ 4_\ 2:9_./BK_P E/3_[%>$_]/8H****]D_-0K^@[_@I'^RX9_\
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M";_1Q<VDL@ @74OB%J_C>PU&*W!2X/A;2Y+B:62WBAM/XE/VCO\ DX7X\?\
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M*C(_N _:H_X.7?V#O@;<W_A[X+V7C7]JCQ=92RP//X'@7P9\,XKBW+)+!/\
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M]RB?,U,YS>M+FJYKF563U<JF.Q4Y7[WE5;/OKPW_ ,%4?^"DGA1XGTO]N/\
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M=?9G_!1O_E(7^WA_V>9^U!_ZN_QQ7QG7V5#^!1_Z]4__ $B)_,^9?\C''_\
M8;BO_3]0****U.(_ID_X-5/^4A?QC_[,S^(7_J[_ -G>O[_*_@#_ .#53_E(
M7\8_^S,_B%_ZN_\ 9WK^_P KXW.O]_G_ ->Z?_I)_2GA?_R2M+_L.QG_ *7
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M3E3BFU_>)17EWP9^-GPG_:'^''AOXN?!+Q[X>^)/PY\6V@O-"\4^&KS[597
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M %OJ.H]?>LR1-I/<'K^/?Z>OO029$B;@>.1U_#^H_P YK-D3:3QP>OX_T/\
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M3(P?;O\ K_\ %?Y%8<;X(]#T_'M_A[U?C?!!['GGM_GH?2@TB^E[]4^Z[?\
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M)_UXI_\ I*"BBBLSM"BBB@ HHHH **** "BBB@ HHHH **** /P!_P"#EO\
MY1>^*O\ LLWP@_\ 3OJ%?YSM?Z,7_!RW_P HO?%7_99OA!_Z=]0K_.=KZ_(O
M]RE_U_J?^DTS^<?%7_DIZ?\ V*\)_P"GL4%%%%>R?FH5_J7?\$;/^47O[%?_
M &1G3/\ T[ZQ7^6C7^I=_P $;/\ E%[^Q7_V1G3/_3OK%>%G_P#NU'_K^O\
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M>)\;Q-CY8BLY4L'2E*.!P7-[F'I-VYI):3Q%1)2K57=MVA!JG"$44445VGS
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M?_JI?A_7Y-5^LO\ P7/_ .4KO[8W_8Y^"_\ U4OP_K\FJ_0,)_NF%_[!Z/\
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M;7S/%/$N%X8RYXNLE5Q59RI8'"<UI8BLE=N36L:%)-2K5+:)QA&]2I"+Q/\
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M\].4H2<6I<LFDU<****LYPHHHH **** "BBB@ KZ4_9(_:O^,7[%7QW\%_M
M_!#7FT?Q=X3NUCO]-N3-)X>\:^%;JXMI-?\  OC#3X983J?A?Q';VT=O?VZR
MP7EE<Q66M:->:;KVE:5J=E\UT5,HQG&4)I2C).,HM733T:9K0KUL-6I8C#U)
MT:]"I"K2JTY.,Z=2$E*$X26JE&233/\ 6_\ V-?VLOAG^VW^SI\.?VC?A5<,
MN@>.=*!U7P_<W$5QJ_@CQ?IY%KXI\$:\8DB']J^'-56:T-R((;?5K V.N:>C
MZ7JEC-+]0U_G_?\ !M%^W-J/P._:IO\ ]DGQ=JS+\*_VH%F?PU;W4S+:>'/C
MAX=TN2YT&_M=Y:*W7QUX>L+SP;J,4<8GU76[?P&C3)%IACE_T :^&S#"?4\3
M.DKNFTITF]W"5[)OJXM.+?6U^I_5G"'$$>(\EH8Z7+'%TV\-CH1T4<52C%RG
M%=(5H2A6@E=151T[MP;"BBBN(^G"BBOYSO\ @OG_ ,%9IOV+?A@G[-?P&\1?
M9?VH/C)X?EFU#Q!I=PHOO@K\,=1-S87/BJ*9 [6GCKQ6T-YI/@A(_+O-%MHM
M5\8^?87FG^&1J^V'H5,35A1I*\IO?I&*WE)](Q6K[[*[:3\S-\VP>29?B,RQ
MT^2AAXWY8V=2M4D[4Z-*+:YJM65HQ5TDKSFXPC*2^:_^"VW_  7BG^!NI>+_
M -C[]BW7XF^,%BUSH'Q@^.>FRQ3P?"F^CE$6H^!?A^6BFMK[XB1(LMGXE\2D
MO:> I&DTK2UN?&J7EUX+_AQU+4M1UG4;_5]7O[W5=6U6]NM2U35-2NI[[4=2
MU&^GDNKV_O[VZDEN;R]O+F66XNKJXEDGN)Y))99'D=F->>>:YFFN;F:6XN+B
M62>>>>1Y9IYI7,DLTTLA9Y)9'9GDD=F=W8LQ))-15]QA,)2P=)4Z:U=G4J/X
MIR[M]$OLQ6D5YMM_RSQ%Q'F'$F.EB\;-QIQ<HX3"1DW0PE)O2$%HI3DDG5K2
M7/5DE>T(PA HHHKJ/ "BBB@ HKMM%^&GQ'\20?:O#OP_\;:_;?8IM2^T:+X4
MUW58/[.M\&>_\ZQL)X_L4 (,UUN\B/(WR+7/:MH6MZ#-';:[H^JZ+<31>?#!
MJVGW>G32P[VC\Z.*\AA>2+>CIYBJ4WJRYRI 5U>UU?M=7^XMTYQBI2A-1>TG
M%J+]&U9[K;N95%%%,@**** /TD_X)L?\%-OCM_P3<^+2>+/A]>2^)_A3XIO]
M-B^+OP:U6\E7PYXWT>VF1)-0TTGS$\.>.],LC,GAWQ9:0O+;LPL-7M=7T*>\
MTJX_TQOV:OVD?A%^UM\%O!/Q\^!WB9/%'P]\=:>UWI]R\1L]5TG4+65[36/#
M?B/2V>272/$?A_4HKC3=7TZ1Y4CN8#/9W-[IT]G?7/\ D*U^X'_!#W_@J!JG
M[ 7[1-KX(^(FNW'_  RQ\<-8T[1?B?I]W/(^G?#[Q+<&'3M ^,.F0,X2SET;
M%OIGC@V^/[6\%--/<6VI:IX9\,16OC9KET<3!UZ,4L1!7:7_ "^BEL^\XI>X
M]W\#O[KC^E\ \9U,EQ5/*LQJN648FHH4Y5)-_P!G5ZDM*L&W:.%J2?\ M%/2
M,&_K$>5JK&K_ *4%%0VUS;WEO;WEG<0W5I=0Q7-K=6TL<]O<V\Z++!<6\\3/
M%-#-$RR12QLT<B,KHQ4@F:OD#^C=]@HHHH *_"S_ (+6?\%<]$_X)Y?"^/X9
M_"RZL=:_:S^*N@W<W@>QD2TO[#X5^&II)=/D^*/BJPN4N(+JX6YCNK7P-X>O
M;=[77-9LKN^U*.?1=$OK#4_U<_:>_:%\"_LH_L__ !7_ &B?B3+*G@_X3^$;
M[Q-J-M;LJ7FL7JO#8:!X;TYW5XUU7Q1XBO=*\.:4TP\@:CJEJ9V2'>Z_Y1O[
M3?[1GQ,_:T^.WQ)_:$^+NKMJWCGXE^(KC6K\1M+_ &=HNG(J6>@>%="AF>22
MT\.^%-#MM/\ #^A6KR2RQ:9IUM]IGN+HSW$OKY3@%BJKJU5>A1:NGM4J;J#_
M +J5I3[IQC:TFU^<^(7%D\@P-/ X"IR9IF$).-1/WL'A4W">(CVJU)7I8=_9
ME&K43YJ45+S7QYX\\9_%'QGXG^(GQ$\3ZUXS\<^,]:OO$/BKQ5XAOIM2UK7=
M:U*=KB]U#4+VX9I)III&.!D1Q1A(84CACCC7DJ**^Q2222222LDM$DMDET2/
MYNE*4Y2G.4ISE)RE*3<I2E)WE*4G=N3;;;;;;=WJ%%%% @HKTOX;_!?XQ?&/
M4#I'PA^$_P 2_BIJJRQP-IGPW\">*?'&H":5HTBA-EX8TK5+D2R-+$L<9BWN
MTL84$NH/U9:?\$L?^"D5[;07</[#?[4*17$231I=_!KQM87*HX#*)[*^TBVO
M+64 _/!<P0S1G*R1JP(J)5:<':=2$7VE.,7]S:.NC@,=B8\^'P6+Q$/YJ.&K
M58_^!4X27XGP117U)X__ &'?VS_A5#<W?Q)_9,_:1\#Z?:K,\VK>)O@G\1])
MT7RK=!)<3Q:W=^'(])N+>!#NEN+>\E@C&2T@P<?+K*R,R.K(Z,5=&!5E920R
MLI *LI!!! ((((S3C*,U>,HR7>+37WILQK8>OAY<F(HU:$_Y:U.=*6F_NSC%
MZ>@VBBBJ,@HHHH _I?\ ^".O_!>?QW^RMJWA7]G/]K?7]8\?_LQWEQ9:'X:\
M>ZD]YK7C;X"PN!;69BE N-2\4_#&T8PI?^'9/M6L^%M.0W?A!KBUL1X3U/\
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MAE^G_P"O_'M[\<UH1OM/!X/^>?;U]/:@LW8I"#@D_P">_P#0^H]:U89/K_\
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M]1N5E)&1N5AG(('VC7CUOXL[=_T5_P 3]'RW_<,)_P!>8?@@HHHK([@HHHH
M**** "BBB@ HHHH **** "BBB@#\ ?\ @Y;_ .47OBK_ ++-\(/_ $[ZA7^<
M[7^C%_P<M_\ *+WQ5_V6;X0?^G?4*_SG:^OR+_<I?]?ZG_I-,_G'Q5_Y*>G_
M -BO"?\ I[%!1117LGYJ%?ZEW_!&S_E%[^Q7_P!D9TS_ -.^L5_EHU_J7?\
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MJX:IJ=*'UK,91M6S"M%>TU5I0PT-5AJ3U]V+=2:TJU:B45$HHHKSSZ\****
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MED[&-(F0<]0/\_CZ5GR)@GT[^^>_]#[^O-;<L>#D \?YQ_4>OO5&5,C/]/\
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MZ=]0K_.=K_1B_P"#EO\ Y1>^*O\ LLWP@_\ 3OJ%?YSM?7Y%_N4O^O\ 4_\
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MD\U8M/\ &OAK3/$=K 7ZE[>+45@D5L.DD;I(JNK*/4*_&?\ X(!_%2;XI_\
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MX#_"/X!>!HEC\+_"3P#X:\#Z9-Y,<$VIMH>FP6VH:]?)$ C:KXBU-;W7=7F
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MWP0.,=O?/;_ _P ZT8WS@@\_S'^>OH?3B@HW(WQR#Q_(_P">OJ/6M.&3Z_\
MZO3W'4>WI6##)D<Y_P ]_P .A]>O-7XGVG'^?_UCM[>E!K"5]'NOR.DB?<,?
MY_#V/;WSUKZZ_9W_ &M_B!\"[BWT=Y'\5_#UY3]K\(:E=.ITY99&DFN_#%\X
ME;1KDRR/--:>5-I5\[S&XLX[N:/4;;XVADZ=/_U_X]1^636G&^<$'GO[C_/7
MT/X5G4IQFFFD^Z[^G6ZZ-6?X'7AL36PU6-2C4E3FMI1^7NR6THNRO&2<7I='
M]-OPL^,7P_\ C5X>'B#P)K,=ZL0B35='N0+77="N9%)%KJVFLS2PDLLBV]Y"
M9].OO*E:PO+I(W9?09$VD^AZ_P"/T/\ ]:OYBO!/CCQ5X UZR\3^#==U#P]K
MMBV;?4+"4(S1EE,EM=02+):W]E,55;JPOH+FRNE4+<02H-M?L=^SW^VWX5^)
M7V'PI\2/L'@SQQ($M[743)]G\*>)+@X54M;BYFD;1=2G;(73M0F:UGD,<=AJ
M,MS<1Z?'YE7#RA>4+RC^*7GW7FMEOW/N,NSRCBN6CBN6C7=HJ6U*J]$K-_!-
MO[,G9NW+)MJ*^V9H^OTSG_/<?J/RK/=,Y!'(_7_/;T/I6VZ8R#^'M_\ 7'?_
M .O6?-'@\8Z_Y'T/4?TKF/9:L[&)*A4DX]<_X_7U_/WJC*G<9_SV_J/7IS6W
M*@8$X]<_X_3U_/WK.=,9!'!_3_/;U'K01)=5OV[KL_Z_0QY4W G_ #_^H]_?
MGFLN:+KQ_D>WJ/U'Y5O2)M)[@]?Q_P ?YU1FCZG_ #Q_4?J/RH,FNJV?X=U\
MOQW.;ECQGCIZ>O\ @>/I[=*H2)D'U[^V._\ 0^WIS6]-%UX_S_@>WH?2LR5"
MI)Y_^M_B.]5&5GY/?_,B4;KS6QB2)@D'H<_Y_P *SYHNO3_/?\>A_/FMR6//
MT_SQZ_3_ ":H.G4''L?\^O0UL8F"Z8R"./Y'_/Z>O-9\T?7_ #U_7!_0_E6[
M-%UX_P ?_P!8[>H]:SW3((/7G'OG_']*"&NCV?POL^WIV^[L<]*F#G^G^>1W
M]O2J,L>1D <_YQ_4>GM6[-'U_P /3^HZ'V]*X?Q-XITKPT@6[<SWTZ;[73;<
MJUU,I8J)7W$);6H97S<SLB,8WB@$]SL@D$KZ(QDU!-R:BENWI_5^G?H2W<UO
M:02W%W-%;6\*&22XGD6**)!U:21RJJHX!+$#./:O,-3\23:DY@T[S;*PR0]T
MZO#?W:Y((@1@LEA 0.)7'VZ17;8EA)$LLO+ZCKNH:]<BXU&1/+1]]M80Y%E9
MG^%D5OFN+D#Y7O)_WFXR&W2SAE:W"QOD#GD=/\/P_45K&"6KU?;I_P $X)UE
M*7NIJ+WV3?F^R[J^O7>QL6ZQPHJ0J$1<G:O'+,79B>2S.[,[.26=V9F8LS$Z
ML4F1CZ?K_C^A_.L*&3IG/I_];\.H_+BM"-\$>AZ?CV_P]ZO<%IMTV-R)^Q]N
M_P"O^/X?2K\4F#@^WZ=/R_4=N*QHWR 1U'\O\\'WJ]&^0.>1T_P_#]16,E9^
M70WB[KSZG002].?R_P _B/Q&:U8I-P _SS_C_.N;ADZ=?_U=OPZ@_AQ6M#+T
M_P ]?Z'M[^M2/8WH9,'!_7^?X]#^!S6C&^""#]?8_P"?S':L.-\X((R/U'^>
M#Z>U:$,@QC/'^?U'?VYYH-XNZ\^IOPR].3_G_#J/RR*THWS@CVS[Y_Q_0UST
M3[3CGV_SZCM^7%:L,G3_ !]?Z'M[^M!<7T?R\GT_K_@F]#+TY'X_S_H?0\\5
MHQO@@@_7V/\ G\QVK C?!'/!Z?7_ #P?3VK4AD![GW_Q^HZ'UZ\T&J?WK?\
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M]--_N,DRB=%K&8J'+5M^YI2^*GS+6I-=)M.T8O6*;<DI642BBBN$^G"BBB@
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M*,4DO)!7^0+^T=_R<+\>/^RS?%#_ -3?7*_U^J_R!?VCO^3A?CQ_V6;XH?\
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M</1BNB5'!X>FTM[7E&4GYMO2X4445Z!\<%%%% !1110 4444 %%%% !1110
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M2_#^OR:K] PG^Z87_L'H_P#IN)_'W$'_ "/L[_[&^9?^IM8****Z#R#]R_\
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MCQ_ZJSQ57^1Q7^N/^VI_R9O^UI_V;-\>/_56>*J_R.*^HX?_ (6(_P"OD/\
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MP^,-89[>**[:7_/XK_9*U_0=$\5:%K7A?Q+I.GZ]X<\2:3J6@^(-#U:TAO\
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M[=_LY?\ !3']@_\ :O>QLO@;^T[\+_$WB34?)6T\"ZSK+^!?B)<2RA=T5GX
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MTK2$NC^7^1G./5?/_,Q)$R#QR.OX=_J*R[A5C5G8JBHI9G9@JJJ@EF9C@*@
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MH1/@@=NWT/4?X5B68EGEB@@C>:::2.*&&)&DEEE=@D<4<: O)(SLJHBJ6<L
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MMX'^:K_X+?\ G_5GY7]G_B%_%?\ SYP/_A;#_P"1_JS\K_P!T5_?Y_Q"J?\
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MID_X-5/^4A?QC_[,S^(7_J[_ -G>O[_*_@#_ .#53_E(7\8_^S,_B%_ZN_\
M9WK^_P KXW.O]_G_ ->Z?_I)_2GA?_R2M+_L.QG_ *7 ****\D_1#_,$_P""
MY_\ RE=_;&_['/P7_P"JE^']?DU7ZR_\%S_^4KO[8W_8Y^"__52_#^OR:K]
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MU]UZ)_P:R?\ !.G2M3M+^^^(_P"UOXEM;:59)M$UOXD?"R#3+] <F"[E\.?
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M-[;PW=G>6DT=S:W=I<QK-;W-M<0L\,]O/"Z2PS1.\<L;JZ,RL"?\:>O[R_\
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M\="O[EO^#3C_ )-Z_:T_[+-X)_\ 4(FK^&FO[EO^#3C_ )-Z_:T_[+-X)_\
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M/\/P_45HPR=.OT_I^'4?EQ5DQ=UYK?\ S-R*3(Q]/U_Q_0_G6A#)@X/;'?\
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M 4444 ?@#_P<M_\ *+WQ5_V6;X0?^G?4*_SG:_T8O^#EO_E%[XJ_[+-\(/\
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M_!IQ_P G"_M:?]D9\$_^IO-7\FM?UE?\&G'_ "<+^UI_V1GP3_ZF\U>?FO\
MR+\3_AA_Z<@?7\!?\E=DO_7^O_ZAX@_N6HHHKX<_JDPO%'AK1/&?AGQ%X/\
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MG3ZOXD\5>*-5LM$T#0],M@#-?:GJNHS6]G9VZ%E0/-*@>1XXDW22(C?P9_\
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MR]QJ&J?#/6W2^F^'?B.X>:XGG>QLK[PWK%Q,\_B#PYJEXEG?6/\ H)?L/_\
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M%OA75;/6_#^NZ7<@^3>Z9JFGS3VEU"65XW,4I,4T<L$JI-%)&O\ CF5^D_\
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M_P#!UI_PC_\ PP]\ _M/D?\ "5?\-6:%_8V[SOM/_"/_ /"HOBY_PDWE;?\
M1_(_M'_A$OM'F_OO,^S>1\GVFOZ@F945G=E1$4L[L0JJJ@EF9B0%50"220
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M\J?OP4444 %?Y O[1W_)POQX_P"RS?%#_P!3?7*_U^J_R!?VCO\ DX7X\?\
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M]AZIHE[>_P"JO7YQ_P#!3O\ X)U?#?\ X*0_LZ:G\+/$K67A[XF^%O[1\2?
M_P")DL#-<>!O&\EHD9MM0D@AGN[GP3XL6UL])\;:1%%.;FQBLM8LH/\ A(-
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MR3]VK["*3O+E]NHHHKY(_H8**** "BBB@ HHHH **** "BBB@ HHHH ****
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MY[_YZ'UK1@DZ?Y_SCM[=JS-HRL_)_AY_U^AT*/T(Q[C_ #Z]16C%(",$]?\
M.?\ 'T/I6%#)TZ?_ *_\>H_+-:,;X(YX/3_#\?T-!L;D4F#@D\?YS_0^OO6B
MC]#^?M^7I_+ZUAQOD CJ/7O_ )Z'^?-:$,G3\NO^>G;V[4#B[._W^AO0R=.G
M_P"O_'J/RR:U8I >,]?Y^O\ 0^A]*YR)]I'/T_'W_45JPR].?3_/X_H>W>@W
M3V:]4;T,F" ?\^_]#ZCUK1C?&"/Q]O\ ]7\OK6'&^0#W'/U_ST-:,,@Z?Y_R
M/Y=JQDK/RZ&T7=>?4W(G##''M_GWZC\LUH0R8P">?\_H?T/:L*)]I SQVQ_G
M\1^6:TD?."/;/N/_ *_Z5)1MQO@@CH?T_P ]#6I!)T_S_G';V[5@PR9&#[=_
MU_H?PYJ_%)@X/M^G3\OU';B@UA*^CW7XHZ.)P0!GZ?7_ .OVK0ADZ#GM_GZ'
M]#^=8,$O3G\OS_\ K@_49K3C?."/;/OG_']#0;0E9VZ/\S;C?!!'0X_#_/0U
MI1OD#U'3_#\/Y5APR CD]?\ .?Z'WJ_%)@@$_IZ=/R_EZT&INPR=.?\ /?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#+,PRJN\-F.#KX.LK^Y7IN*DEIS4YZPJP[3IRG!]),91116IPA1110 4444
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MXSQ3C:GAU)6G2P<)+F@FKQG7E:K5C=6IPDZ04445YA]T%%%% 'Y3_P#!3/\
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MPTNHZWJLZJJR7VHW,\RQ+';0F&UA@@C]75550J@*J@*JJ %50,  #@ #@ <
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M3<G36*PU'$*FY6YG!5H34'+ECS.-K\JOLC\FO^'&'_!*+_HSGP9_X6GQ:_\
MG@4?\.,/^"47_1G/@S_PM/BU_P#/ K]9:*T^MXO_ *"<1_X.J?\ R1Q?ZO9!
M_P!"/)__  V8+_Y1Y+[C\FO^'&'_  2B_P"C.?!G_A:?%K_YX%?3G[,?_!/K
M]CK]C77?$_B;]F?X(:%\*==\9Z39Z%XFU#2==\9ZO)JVDV%X=0M+.:/Q/XDU
MR"%(+QC.KVL4$S,=KR,GRU]DT5,L3B)Q<9UZTXO>,JLY1>M]4Y-/775;FU#)
M<GPU6%?#93EN'KTVW3K4,!A:56#:<6X5*=*,XMQ;BW%JZ;6P4445B>D%%%%
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M5E,.F>([7P[\7?"FGRG/D?8]/N4\#^*GMXR?WL5_XWOIY@ $NX#DG\[O&/\
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M*E2IE^$G4J3F^:<YSE1<I3E+WI2DVY/5ML_)K_AQA_P2B_Z,Y\&?^%I\6O\
MYX%'_#C#_@E%_P!&<^#/_"T^+7_SP*_66BG];Q?_ $$XC_P=4_\ DB/]7L@_
MZ$>3_P#ALP7_ ,H\E]Q^?_P$_P""67[ G[+_ ,3-&^,?P&_9Q\-?#OXE^'[3
M6+#1_%6F^)?B!J5W8VFOZ7=:-J\,=IK_ (NU;3'6]TR\N;1VFL9'1)6>%HY0
MKK^@%%%93J5*KYJDYU)6MS3E*;LKM*\FW9-MVVU9WX7!X3!4W1P6%PV$I.;J
M.EA:%+#TW-J,7-PI1A%S<8QBY-7:C%-V2L4445!TA1110 4444 %?#?[2O\
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MBU_\\"C_ (<8?\$HO^C.?!G_ (6GQ:_^>!7ZRT5I];Q?_03B/_!U3_Y(Y/\
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M 'M45O\ VUC[6YZ?K[.-_P#+\#R_^(8\)\U_JV+M_+]=K<OWWYO_ "8_B_\
MAY_P:6:J\\-Q\6/VU-/MK9'C-QH_P\^#-S?3W,?VB82I#XC\2>/]/CLG^RI
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>rvmd-20250507.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-07T13:15:43.4625+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.revolutionmedicines.com/20250507" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:rvmd="http://www.revolutionmedicines.com/20250507" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rvmd-20250507.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rvmd-20250507.xsd#rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member" xlink:label="rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rvmd-20250507.xsd#rvmd_CommonStock00001ParValuePerShareMember" xlink:label="rvmd_CommonStock00001ParValuePerShareMember"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase 0.1112 Shares Of Common Stock Expiring 2026 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants To Purchase 0.1112 Shares Of Common Stock Expiring 2026 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rvmd_CommonStock00001ParValuePerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock 0.0001 Par Value Per Share [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rvmd_CommonStock00001ParValuePerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock 0.0001 Par Value Per Share [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member" xlink:to="rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvmd_CommonStock00001ParValuePerShareMember" xlink:to="rvmd_CommonStock00001ParValuePerShareMember_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rvmd-20250507.xsd#rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member" xlink:label="rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="rvmd-20250507.xsd#rvmd_CommonStock00001ParValuePerShareMember" xlink:label="rvmd_CommonStock00001ParValuePerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="9000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="9100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member" order="12005.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="11000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="9050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rvmd_CommonStock00001ParValuePerShareMember" order="12014.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="rvmd-20250507.xsd#rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member" xlink:label="rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
          <link:loc xlink:type="locator" xlink:href="rvmd-20250507.xsd#rvmd_CommonStock00001ParValuePerShareMember" xlink:label="rvmd_CommonStock00001ParValuePerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:definitionArc xlink:type="arc" order="9000.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable"/>
          <link:definitionArc xlink:type="arc" order="12005.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member"/>
          <link:definitionArc xlink:type="arc" order="11000.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain"/>
          <link:definitionArc xlink:type="arc" order="11000.1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2"/>
          <link:definitionArc xlink:type="arc" order="11000.1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis"/>
          <link:definitionArc xlink:type="arc" order="12014.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rvmd_CommonStock00001ParValuePerShareMember"/>
          <link:definitionArc xlink:type="arc" order="10010.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag"/>
          <link:definitionArc xlink:type="arc" order="10130.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode"/>
          <link:definitionArc xlink:type="arc" order="10020.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate"/>
          <link:definitionArc xlink:type="arc" order="10000.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType"/>
          <link:definitionArc xlink:type="arc" order="10090.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1"/>
          <link:definitionArc xlink:type="arc" order="10100.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown"/>
          <link:definitionArc xlink:type="arc" order="10120.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode"/>
          <link:definitionArc xlink:type="arc" order="10110.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince"/>
          <link:definitionArc xlink:type="arc" order="10040.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey"/>
          <link:definitionArc xlink:type="arc" order="10050.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany"/>
          <link:definitionArc xlink:type="arc" order="10060.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber"/>
          <link:definitionArc xlink:type="arc" order="10070.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode"/>
          <link:definitionArc xlink:type="arc" order="10030.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName"/>
          <link:definitionArc xlink:type="arc" order="10080.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber"/>
          <link:definitionArc xlink:type="arc" order="10140.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber"/>
          <link:definitionArc xlink:type="arc" order="10190.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer"/>
          <link:definitionArc xlink:type="arc" order="10180.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer"/>
          <link:definitionArc xlink:type="arc" order="10210.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle"/>
          <link:definitionArc xlink:type="arc" order="10340.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName"/>
          <link:definitionArc xlink:type="arc" order="10170.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial"/>
          <link:definitionArc xlink:type="arc" order="10220.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol"/>
          <link:definitionArc xlink:type="arc" order="10160.0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications"/>
        </link:definitionLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member" name="WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rvmd_CommonStock00001ParValuePerShareMember" name="CommonStock00001ParValuePerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  07,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Revolution Medicines, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2029180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 Saginaw Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">481-6801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member', window );">Warrants To Purchase 0.1112 Shares Of Common Stock Expiring 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase 0.1112 shares of common stock expiring 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RVMDW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rvmd_CommonStock00001ParValuePerShareMember', window );">Common Stock 0.0001 Par Value Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RVMD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rvmd_CommonStock00001ParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rvmd_CommonStock00001ParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *2 IUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( *2 IUH#7ET [@   "L"   1
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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MQZ%MMTL[%,'JYEC=4["N0Z[6(EJ3WV"\V9"Q#&,6E<+A>E7IULNY>J=PW8B
MD[LD7')5QH)KP#R=-WHN[2$\U"FZJW,*$:2#5+%4:?LZ(PL#-4"D@AE+(+(0
M8.F7IEZ%^N0:@SRP 'H*Y#U[)K<^I)I8"2]KM,<GL4*RV3F'.NW1KH,1%B9
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M>:;7-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @ I("G6B0>FZ*M
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "D@*=: UY= .X    K @  $0
M            @ '#    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "D
M@*=:F5R<(Q &  "<)P  $P              @ '@ 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( *2 IUJ(%9&0 P4  *,5   8
M  " @2$(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "D
M@*=:GZ ;\+$"  #B#   #0              @ %:#0  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( *2 IUJ7BKL<P    !,"   +              "  380
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( *2 IUHZJJ+G0 $  #P"   /
M          "  1\1  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "D@*=:
M)!Z;HJT   #X 0  &@              @ &,$@  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " "D@*=:99!YDAD!  #/ P  $P
M        @ %Q$P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(  "[%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rvmd-20250507.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="rvmd-20250507.htm">rvmd-20250507.htm</File>
    <File>rvmd-20250507.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rvmd-20250507.htm": {
   "nsprefix": "rvmd",
   "nsuri": "http://www.revolutionmedicines.com/20250507",
   "dts": {
    "inline": {
     "local": [
      "rvmd-20250507.htm"
     ]
    },
    "schema": {
     "local": [
      "rvmd-20250507.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 25
   },
   "report": {
    "R1": {
     "role": "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_1078c484-edf1-40c0-b029-9033e5efacfe",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rvmd-20250507.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1078c484-edf1-40c0-b029-9033e5efacfe",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rvmd-20250507.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "rvmd_CommonStock00001ParValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.revolutionmedicines.com/20250507",
     "localname": "CommonStock00001ParValuePerShareMember",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock 0.0001 Par Value Per Share [Member]",
        "documentation": "Common Stock 0.0001 Par Value Per Share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "rvmd_WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.revolutionmedicines.com/20250507",
     "localname": "WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants To Purchase 0.1112 Shares Of Common Stock Expiring 2026 [Member]",
        "documentation": "Warrants To Purchase 0.1112 Shares Of Common Stock Expiring 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.revolutionmedicines.com/20250507/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-065618-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-065618-xbrl.zip
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M@MX=NE1WL%^HL'&9737A ]0UK%'!04$OA>B/"T>B"'0']8>IP@ G13B+.</
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MMHF11"\E)<Z_7Y)ZRY1,R]:C'@V*B2-1E^>0ER)Y[C7SX;>U;8$G2%R$G>E
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M*($TY6YZ\6XQ!EFRXVZNFV1B%;(43[HY2F7C'=)NV\V952YJ(NVNW=S3; W
M2'=B-U> 6V,X86YW-G<[NAT=/$[_-]-=&%S^H*Y=<Z*O5HC6SRZ%%QP'![GA
M_!J[!(,P#D#F04Z1<>@XFP[VLQ%TG>D1A7UR)T%3LZ8+,MM<?^;2-0?/1*>[
M W\U';!N0A-$BP3=BR8KKDX]!J9\$AZ$[B#+8K)S%-+2PY.2PM_5XF:1S?@,
M&D"V=*M4 Y]PC26T]8__!U!+ P04    " "D@*=:-G,&&(@I  !Y7P( #P
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M1(&Q4-#1A0'Y=CFL@BL](%1%J 50C(W8&[%_#2L>>]'0!SMUB8ZSQ\F?8-W
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M3M RV<J.[!NC2Y_:+(+U<M/<_-3MQ P]&2DX ]@A:;J7&;>D?IIN7_.42[O
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MK>PA#%)_8#9H&8';7E"M:G/9M)FNR*5[$IL'&?Y/6#W'W\OVK<YE?;)?9C-
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M;/BFH'RS9C;)MFH8Q6[$WS 3%*PN'^;Q1@OZ^JQD6*/I2L2Q3\BMP)5SA[N
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MOJI^J?K46+A.G[2,R+&\]FBVGB?[L\JCT:BU7Z,['M<7KY5D*H0/X=DTU[A
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M*,D)L?_L",Y.:OA>%D220HA*#95A=.E#93%!@-%Q&>\9ME\D/HBB3F;"*^+
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M @ /              "  ?TA  !R=FUD+65X.3E?,2YH=&U02P4&      ,
, P"[    LDL

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>rvmd-20250507_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rvmd="http://www.revolutionmedicines.com/20250507"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rvmd-20250507.xsd" xlink:type="simple"/>
    <context id="C_1078c484-edf1-40c0-b029-9033e5efacfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628171</identifier>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <context id="C_5c9cfa7a-b8da-4cf8-99ca-91f02e0e9887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628171</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rvmd:WarrantsToPurchase01112SharesOfCommonStockExpiring2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <context id="C_6b5f0c1d-63de-4699-b182-dc1b9bf951ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628171</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rvmd:CommonStock00001ParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_788a7e4e-8088-4a9d-b94e-871f682d4152">0001628171</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_568e1637-d34c-459f-ba60-7f77e0b2ebba">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_4410ee01-7184-43bd-94a0-ede9fb8062f6">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_d9022b5e-e0f1-4feb-acf7-08df08e0a6ec">2025-05-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_01bcf545-306c-426f-94ae-90740e06e8d6">Revolution Medicines, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_546d3bfc-f626-46fa-a862-ce5869c769cb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_43ce771a-f29e-48dc-9809-36df2915e7bc">001-39219</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_6c3954be-9cfe-4abd-8046-cad8c357a6c7">47-2029180</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_ad9fca0f-72a5-4377-bbc0-6e103bccd2f3">700 Saginaw Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_b7e12a65-a97f-46d5-a910-13ad6028de46">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_65d55536-12d1-49df-b223-c607a971c8e6">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_50196c82-16c7-41c7-afd4-86e72cad63fb">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_120c8136-5962-4a86-a605-c271afd26f3b">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_994e511f-e53e-442b-9061-1d96781ef4ce">481-6801</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_8bf4912b-0d88-40c7-aa67-2c267b43756d">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_f700e850-d1e0-4379-bd6e-a624cd70369e">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_6f9b6bfc-4bfc-486c-8345-47a9966280b4">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_0c047a7b-9a65-4acb-bbd4-9ad47bea6108">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_6b5f0c1d-63de-4699-b182-dc1b9bf951ec"
      id="F_b327b2c7-f051-4268-8665-ca375934f270">Common Stock $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_6b5f0c1d-63de-4699-b182-dc1b9bf951ec"
      id="F_71497839-a898-415f-b6fc-aa429f890312">RVMD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_6b5f0c1d-63de-4699-b182-dc1b9bf951ec"
      id="F_5d61bf29-30c2-477c-ba5f-c8ea4a0544a5">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="C_5c9cfa7a-b8da-4cf8-99ca-91f02e0e9887"
      id="F_418e1fc5-73be-4c04-8323-e9dd30e3018b">Warrants to purchase 0.1112 shares of common stock expiring 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_5c9cfa7a-b8da-4cf8-99ca-91f02e0e9887"
      id="F_1a172c00-1e6b-44da-8256-270014990e7e">RVMDW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_5c9cfa7a-b8da-4cf8-99ca-91f02e0e9887"
      id="F_9d1a2e28-06c5-4587-86b0-792355c12c12">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_1078c484-edf1-40c0-b029-9033e5efacfe"
      id="F_ba2085c1-0333-4d3b-b9c5-a98e600a1d3e">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
